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Structure of the work—The first section of this thesis gives a brief overview of the literature about the transcription
factor Sox9, focusing the attention on its main functions during developmental processes and in acquired diseases. The
second section, after a short introduction on Sox9 in Veterinary Medicine, is concerned with the assessment of Sox9 im-
munohistochemical staining in normal tissues of various animal species, in order to validate this marker in domestic
animals. The other sections present the findings of the research, with six original research studies concerning Sox9 im-
munohistochemical expression in several groups of neoplasms. To better explain Sox9 role in nervous tissue development
and in its neoplastic lesions they are treated together with Sox10 in the last work. To conclude, an appendix with other
publications/communications realized during the 3-academic-year–period (end of 2012, beginning 2016).
3Sox family transcription factors is one of the earliest class
of master regulatory genes coordinating the main phases
of embryonic development (Chew and Gallo, 2009). They
regulate and organize precise activation and silencing of
gene expression during cell, tissue differentiation and
organogenesis (Pritchett et al., 2011). They are involved in
adult tissue homeostasis and regeneration, as cellular
turnover or wound healing, they are able to reprogram dif-
ferentiated cells into somatic or pluripotent stem cells, or
they can even maintain stem cell state (Sarkar and
Hochedlinger, 2013). Sox transcription factors are ex-
pressed in multiple types of stem cells and progenitor cells
types, but Sox factors can be expressed at subsequent
stages of differentiation within a cell lineage or in com-
plementary patterns within a developing or adult tissue
(Sarkar and Hochedlinger, 2013).
Sox family identification is related to the identification
of a gene responsible for testis determination in mammals
(sex determining region Y –SRY-) (Sinclair et al., 1990).
Sry transcription factors conserve a characteristic 79
amino acid DNA binding domain known as High Mo-
bility Group (HMG) box (Wegner, 1999). Proteins show-
ing at least 50% amino acid similarity with the HMG
domain of Sry are grouped into Sox (SRY box-containing)
family (Gubbay et al., 1990). Outside the HMG domain,
SOX sequences are quite variable suggesting recent shared
ancestry (Bowles et al., 2000). To date, about 20 SOX pro-
teins and their genes have been identified in vertebrates,
while 8 in Drosophila (Kamachi et al., 2000; Chew and
Gallo, 2009). According to Sox HMG similarities Wright
et al., (1993) classified the known murine Sox genes into
6 groups (A-F). Further studies allowed to confirm Wright
first classification and to introduce 4 more Sox protein
groups (G-J) (Table I) (Bowles et al., 2000). Sox members
within a group share an HMG domain with more than
80% identity and strong homologies in amino acid se-
quence and structural organization even outside the
HMG domain (Wegner, 2010; Sarkar and Hochedlinger,
2013; Kamachi and Kondoh, 2013). The amino acid se-
quence identity of the HMG domain decreases to ~60%
between distant groups (Kamachi et al., 2000). Thus,
members of the same group show similar biochemical
properties and overlapping functions, while Sox proteins
from different groups have distinct functional properties
despite recognizing the same domain (Wegner, 2010;
Sarkar and Hochedlinger, 2013). Each Sox protein is able
to play different roles in different tissues depending on
both cellular and target gene context. Frequently, members
of the same Sox group co-regulating the same target are
expressed in the same developing tissues with small differ-
ences in spatio-temporal patterns. This redundancy be-
tween the group members with equivalent functions
safeguards the developmental processes against genetic
variations. Anyway, modifications induced by individual
members of a Sox group to a developmental process are
not always equivalent, with regard to the timing of expres-
sion, expression levels and the activity of a protein (Ka-
machi and Kondoh, 2013). This Sox functional versatility
is further achieved through different molecular mecha-
nisms as interaction with specific cofactors, homo- or het-
erodimerization among Sox proteins, post-translational
modifications (Kamaki et al., 2000; Chew and Gallo 2009;
Sarkar and Hochedlinger, 2013; Kamachi and Kondoh,
2013). Sox genes moreover are often controlled by other
sox proteins or subjected to auto-regulation. Their func-
tion, indeed, is known to be dose-dependent (Kamachi
and Kondoh, 2013). In this way, each protein is expressed
in many different cellular contexts and a specific cell type
can co-express many Sox factors (Wegner, 1999; Chew
and Gallo, 2009). Sox genes has emerged as potent mod-
ulator factors in developmental processes, tissue homeosta-
sis and stem cells maintenance and their role have been
investigating in several diseases, cancerogenesis included
(Pritchett at al., 2011).
Sox9
An introduction
Sox9 is part of the SoxE group, together with Sox8 and
Sox10. Their protein organization show a total length of
300-500 amino acids with HMG domain located close to
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4the N-terminus and an activation domain in the C-termi-
nal region (Kamachi and Kondoh, 2013). Sox9 mutations
were identified as responsible for campomelic dysplasia
(Foster et al., 1994). Campomelic dysplasia (CD) is a rare,
often fatal congenital skeletal malformation syndrome re-
lated to an autosomal dominant condition caused by hap-
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Sox Family Sox Member Foetus Adult Functions
Sox A SRY Gonad Testis
Hypothalamus
Midbrain
Testis determination.
Expression/role in SCs undefined.
Sox B1 Sox1 NPCs
Lens
NPCs Specification and maintenance of
undifferentiated SCs.
Knockout mice show microph-
thalmia, cataracts.
Sox2 NPCs
Trachea
Lung
Tongue
Esophagus
Stomach
Anus
Cervix
Inner ear
Lens
Teeth 
Skin
Bone
Ovary
Testis
NPCs
Trachea
Lung
Tongue
Esophagus
Stomach
Anus
Cervix
Inner ear
Lens
Teeth
Skin
Bone
Ovary
Testis
Development regulator.
Sox3 NPCs
Lens
Spermatogonia Specification and maintenance of
undifferentiated SCs.
Genetic deletion leads to loss of un-
differentiated spermatogonia.
May act redundantly with Sox1 and
Sox2.
Sox B2 Sox14 NPCs N/A Transcriptional repressor.
Specification of a subset of ventral
interneurons in the spinal cord and
neuronal subtypes in the brain.
Sox21 Hair bulge
Developing CNS
Hair bulge N/A
Sox C Sox4 Developing neurons
Early embryonic cells
N/A Organ hypoplasia in case of deletion
Roles in cardiac outflow tract devel-
opment and B-cell development re-
vealed by phenotype of knockout
mice.
Sox11 Developing neurons
Early embryonic cells^
Kidney^ Organ hypoplasia in case of dele-
tion.^
Sox12 ^ ^ ^
Table I. Sox genes with their main target organs and functions.
5loinsufficiency of Sox9 (Kwok et al., 1995). This syndrome
is characterized, in various extent, by short stature, bowing
of the long bones, hypoplasia of the scapula, abnormal
pelvic bones, talipes equinovarus, narrow iliac wings, small
thorax, 11 pairs of ribs. Other anomalies include low ears,
long philtrum, micrognathia, depressed nasal bridge, car-
Sox Family Sox Member Foetus Adult Functions
Sox D Sox5
Sox6
Chondrocytes^ Chondrocytes
Oligodendrocytes
Neocortex neurons^
In case of defects: chondrogenesis
defects, precocious oligodendrocyte
differentiation, alopecia, aberrant
histogenesis of the neocortex.
May act redundantly and both inter-
act with Sox9.
Sox13 Arteries
Thymus
^ N/A
Sox23 Ovary
Brain
Homodimerization.
Sox E Sox 8 Neural crest SCs
Branchial arches
Limb
Heart
Dorsal root ganglia
Testes
Muscle satellite cells N/A
Sox9 Hair follicle SCs
Chondrocytes 
Gonad
Lung
Retinal progenitor cells
NPSCs
Neural crest SCs
Oligodendrocytes progenitors
Glial progenitors
Pancreatic progenitors
Hair follicle SCs
Oligodendrocytes
NPSCs
Exocrine pancreatic duct cells
Liver duct cells
Intestinal SCs
Mammary SCs
Chondrocytes
Specification and maintenance of
undifferentiated SCs.
Genetic deletion leads to alopecia,
failure of neural SCs and mammary
gland SCs maintenance, loss of SCs
differentiation potential to Muller
glial lineage, loss of pancreatic pro-
genitors, chondrogenesis and otic
placode invagination defects.
Sox10 Neural crest SCs
(melanocytes and Schwann
cells)
Oligodendrocytes progenitors
N/A
Oligodendrocytes
Maintenance of stem cells.
Sox F Sox7 ^ Endoderm Gut defects in case of deletion
Sox17 Hematopoietic SCs
Extraembryonic endoderm
SCs in preimplantation em-
bryo
N/A
Vascular endothelium
Endoderm
Spermatogenesis 
Gut defects in case of deletion
Spermatogenesis
Sox18 Blood vessel Dermal papilla of hair follicle
Lymphatic endothelium
Vascular endothelium
Blood vessel and hair follicle devel-
opment 
Sox G Sox15 N/A Satellite cells Inhibitor of myoblast differentiation 
Sox16 N/A N/A N/A
Sox20 Fetal testes N/A N/A
Sox H Sox30 Male germ cells N/A N/A
Sox I Sox31 Late blastula, gastrula, and
neural tissues
N/A Neural induction
Sox J SoxJ N/A N/A N/A
Table legend. NPCs = neural progenitor cells, SC = stem cell, ^ = expression/role in stem cells largely undefined, N/A =  not
assessed yet (data from: Bowles et al., 2000; Sarkar and Hockedlinger, 2013; Kamachi and Kondoh, 2013).
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6diac and renal defects, absence of the olfactory bulbs, di-
latation of cerebral ventricles (Kwok et al., 1995). Male to
female sex reversal (XY-female) is often observed in CD
patients, with genital morphological anomalies ranging
from minor conditions such as hypospadia and cleft scro-
tum to female genitalia with streak-like gonadal rudi-
ments. This variety in phenotypes demonstrates that Sox9
plays a key role not only in cartilage and skeletal develop-
ment but even in sex determination (Kent et al., 1996).
Sox9, of primary importance for cartilage differentia-
tion (Akiyama and Lefebvre, 2011), is moreover involved
in a wide variety of embryonic developmental processes
and in differentiation of several tissues and organs, includ-
ing testis, pancreas, intestine, brain, kidney, lung, heart
valves, bile ducts, hair follicles and derivatives of neural
crest (Akiyama et al., 2004; Vidal et al., 2005; Sakai et al.,
2006; Seymour et al., 2007; Davis and Zur Nieden, 2008;
Akiyama, 2008; Barrionuevo and Scherer, 2010; Antoniou
et al., 2010; Pritchett et al., 2011; Zhu et al., 2012). Sox9
is required at the right time, place and amount during de-
velopment: that is why inappropriate or ectopic expression
can result in disease (Pritchett at al., 2011). In recent years,
indeed, the role of Sox9 in several disease states, as fibrosis
or sclerosis and even cancer, has emerged (Pritchett et al.,
2011). Sox9 expression has been reported in several adult
organs such as intestine, pancreas, testis and skin (Nowak
et al., 2008); many of its functions have been investigated
and explained during these years, but further studies are
needed to better understand its role in postnatal tissues
homeostasis.
Sox9 in tissues
Cartilage
Sox9 plays an essential role in determining chondrocyte
fate and differentiation during embryonic and postnatal
development of bone tissue through a process known as
endochondral ossification (Akiyama and Lefebvre, 2011).
To activate genes encoding for cartilage-specific extracel-
lular matrix (ECM) components, such as Collagens and
Aggrecan, Sox9 works together with Sox5 and Sox6 (the
Sox-trio) (Pritchett et al., 2011).
Sox9 has been demonstrated to be of primary impor-
tance in the early phases of cartilage differentiation of
mesenchymal stem cells; its expression is detected in all
chondroprogenitors and differentiated chondrocytes until
the cells in the growth plate develop into hypertrophic
chondrocytes (Akiyama, 2008). As reported above, muta-
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tions in this gene can lead to a severe skeletal malforma-
tion syndrome (Bi et al., 2001; Akiyama and Lefebvre,
2011). The effects of Sox9 gene mutations have been stud-
ied in Sox9+/- mutant mice too. Sox9+/- mice die shortly
after birth with skeletal alterations, such as bowing of long
bones and hypoplasia of various skeletal elements, that
strongly resemble the CD ones. Embryo skeletal analysis
revealed abnormalities in cartilage primordia, impaired de-
velopment of pre-cartilaginous mesenchyme, that was de-
layed and smaller in size, and premature skeletal
mineralization (Bi et al., 2001). Many signalling pathways
regulate Sox9 expression during chondrogenesis and bone
repair either directly or indirectly; inappropriate Sox9
pathways activation with excessive or ectopic ECM dep-
osition can lead to fibrosis and related disorders (Pritchett
et al., 2011). 
Pancreas
Examinations of CD cases revealed abnormal pancreatic
morphology, with epithelial cells less densely packed and
islet less clearly formed with variable expression of hor-
mone and beta-cell markers (Piper et al., 2002). 
Several members of Sox family, Sox9 included, have
been investigated for their role in mice pancreas develop-
ment, especially in endoderm specification, beta cell pro-
liferation, insulin secretion, endocrine cell differentiation
and pancreatic stem cells maintenance (McDonald et al.,
2012). Inactivation of Sox9 in mouse pancreas leads to sig-
nificant depletion of pancreatic progenitor cells, resulting
in pancreatic hypoplasia (McDonald et al., 2012). Only
Sox9 expression has been detected in the developing and
in the adult human pancreas (Piper et al., 2002). Sox9 is
important for the maintenance of early pancreatic progen-
itors; moreover it determines their endocrine fate, because
formation of endocrine progenitors is sensitive to Sox9
gene dosage. On the other hand, formation of exocrine
progenitors is insensitive to reduced Sox9 gene dosage
(Seymur et al., 2007).
In the first embryo developmental stages, Sox9 is de-
tectable in the precursor cell population that will give rise
to intestinal epithelium, hepatic ductal cells and
exocrine/endocrine pancreatic cells. Later, Sox9 detection
becomes restricted to the pancreatic ducts. Sox9 embry-
onic pancreatic progenitors lose their capacity for en-
docrine differentiation shortly after birth, at time of
Langerhans islet formation (Furuyama et al., 2011). In
adult, pancreatic exocrine and endocrine functions are me-
diated separately by independent functional units, repre-
sented respectively by pancreatic acinus and islet of
Langerhans. The functional units of intestine, liver and ex-
7ocrine pancreas receive a continuous supply of cells from
a common Sox9-positive progenitor zone; the islet of
Langerhans, on the other hand, lose their histological con-
nection to the ductal tree and do not receive cells from this
Sox9-positive precursors (Furuyama et al., 2011). In adult,
indeed, Sox9 is expressed in intestinal crypts, pancreatic
ducts and bile ducts. In pancreas, it is present in duct cells,
centroacinar cells included, but not in exocrine acinar cells
or in endocrine islet cells (Furuyama et al., 2011).
In adult man, pancreatic progenitor pool seems to be
limited to a subset of ductal and centroacinar cells, hy-
pothesized to be the pancreatic stem cell compartment
(Belo et al., 2013). 
Liver and gastrointestinal tract
The upper digestive tract includes organs as the liver, pan-
creas, and duodenum. They derive from the primitive
foregut endoderm of the embryo, and share Sox9 expres-
sion in their progenitor populations ( Jo et al., 2014). Be-
cause of this, there is a contiguous Sox9 expression in the
liver, pancreas and intestine; this progenitor zone involves
hepatic and pancreatic ductal tree and intestinal crypt, and
is anatomically connected through the duodenal papilla
(Furuyama et al., 2011).
With regard to liver, hepatoblasts are the precursors of
both embryonic hepatocytes and bile duct cells. Sox9 is
absent in hepatocytes, the cells that secrete bile, but instead
is detected in cholangiocytes and mucin-producing cells
of bile ducts (Carpino et al., 2011; Jo et al., 2014).
Sox9 starts to be detected in the extrahepatic biliary
tract at embryonic day 13.5 and retained at the adult
stages. During mid-to-late embryogenesis Sox9 expres-
sion begins to be detected in the intrahepatic bile duct
cells, when the structure of the ductal tree starts to develop
in preparation for the adult function of the liver as meta-
bolic organ. In early embryonic stages, indeed, the liver is
a hematopoietic organ. As the intrahepatic ductal tree de-
velops, Sox9 negative hepatoblasts switch to Sox9 positive
embryonic hepatocyte progenitors. At the late embryonic
stages intrahepatic and extrahepatic bile duct will connect
(Furuyama et al., 2011). 
Evidence suggests that Sox9 determines the timing of
bile duct morphogenesis: the biliary tube is entirely com-
posed of Sox9 positive cholangiocytes, and liver inactiva-
tion of Sox9 results in delayed duct maturation ( Jo et al.,
2014). Further studies showed involvement of Sox9 posi-
tive cells in liver regeneration by mean of lineage analysis
and hepatic injury experiments: it seems that cells located
at the junction of the duct structure and the functioning
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units of the liver (canal of Hering) are the Sox9 expressing
cells representing the progenitor cells of the liver involved
in tissue homeostasis maintenance (Furuyama et al., 2011).
A recent surprising data is that Sox9 positive cells in the
liver can be reprogrammed into insulin-secreting duct
cells, implying that developmentally related cells can be
modified to be used in a potential therapy for diabetes ( Jo
et al., 2014). 
During duodenal development, Sox9 is expressed in
most early epithelial progenitors and becomes gradually
restricted to the nuclei of crypt cells, stem cells in the lower
crypts, as well mature Paneth cells, enteroendocrine cells
and in a subset of Transit-amplifying cells that orchestrate
stem cell activity and tissue regeneration (Mori-Akiyama
et al., 2007; Belo, 2013; Hsu et al., 2014). Sox9 indeed is
required for the differentiation of Paneth cells in the in-
testinal epithelium. In the absence of Sox9, Paneth cells
were not formed, crypts were enlarged due to a marked in-
crease in cell proliferation throughout the crypts, and
Paneth cells were replaced by proliferating epithelial cells
(Mori-Akiyama et al., 2007). Sox9 expression in intestinal
crypt cells is regulated by the Wnt/β-catenin signaling
pathway, which has been identified as one of the key path-
ways in the initiation and development of colorectal cancer
and in gastrulation and morphogenesis and maintenance
of crypt stem cell self-renewal (Sun et al., 2012). Intestinal
Sox9-expressing progenitors indeed are capable to retain
multipotency from the early developmental stages
throughout the lifespan (Furuyama et al., 2011). In human
embryonic tissues at 7.5 weeks gestational age, mesoder-
mal Sox9 expression is detected in the posterior region of
the stomach at the pyloric area (Kimura et al., 2011). Sox9
indeed specifies the pyloric sphincter epithelium through
mesenchymal to epithelial transition signals (Moniot,
2004). However, Sox9 expression in human adult stomach
has not yet been clarified (Kimura et al., 2011). Inactiva-
tion of the Sox9 gene in the intestinal epithelium alters
the morphology of the colon epithelium with hyperplastic
appearance and local crypt dysplasia confirming a regulat-
ing role for Sox9 in cell proliferation (Kimura et al., 2011).
Sox9 in vivo, indeed, suppresses proliferation in mouse in-
testinal epithelium, while inactivation of Sox9 results in
increased proliferation ( Jo et al., 2014).
Lung
Lung originates from cells of the foregut of early embryo
and subsequently differentiates into multiple lineages of
lung cell types (Zhu et al., 2012). 
The morphogenesis of the lung, as well as the injury re-
pair of the adult lung, is tightly controlled by a network of
8signaling pathways with key transcriptional factors, and
Sox9 is one of them (Zhu et al., 2012). Sox9 regulates lung
epithelial development during lung branching (Chang et
al., 2013; Jo et al., 2014). Up to now several studies have
attempted to point out its role in lung branching program,
but with conflicting results, maybe due to the different ge-
netic line of the mice employed ( Jo et al., 2014). In a study,
Sox9 inactivation resulted in substantial no alterations in
lung structure, postnatal survival and recovery after oxygen
injury (Perl et al., 2005). On the other hand, other inves-
tigations revealed aberrant epithelial movements, cy-
toscheletal disorganization and defects in extracellular
matrix (Chang et al., 2013; Rockich et al., 2013). More-
over, transgenic mice lacking Sox9 expression, showed a
tracheal collapse because cartilage rings were missing; mu-
tant mice were unable to breathe and died at birth,
demonstrating the importance of Sox9 in tracheal devel-
opment too (Turcatel et al., 2013). Sox9 indeed is highly
expressed throughout lung morphogenesis as a down-
stream gene of Sonic Hedgehog (Shh) (Zhu et al., 2012);
Shh is a glycoprotein expressed in the notochord and floor
plate that upregulates Sox9 to generate chondrogenic pre-
cursors. In this way, Shh signalling controls the patterning
and formation of tracheal cartilage by means of spatio-
temporal regulation of Sox9 (Park et al., 2010; Jo et al.,
2014).
Sox genes seem to have an oncogenic potential in lung
cancer; overexpression of Sox9 seems to promote lung
adenocarcinoma cell proliferation (Zhu et al., 2012).
Heart
Epithelial-to-mesenchymal transition (EMT) is a process
occurring repeatedly throughout embryogenesis (Pritchett
et al., 2011) and is involved in the formation of endocar-
dial cushions, primordia of valves and septa too (Akiyama
et al., 2004). In CD patients ventricular septal defects and
Fallot tetralogy have been signalled (Montero et al., 2002;
Sanchez-Castro et al., 2013). Sox9 and SoxE genes play
an important role in cardiac septa formation and valvulo-
genesis; indeed they seem to be responsible for connective
tissue differentiation. Sox9 in particular, together with
other Sox proteins, regulates aggrecan and type II Colla-
gen genes expression: these are extracellular matrix com-
ponents of the cushion tissue mesenchyme and developing
valve (Montero et al., 2002). Previous work on chick em-
bryos showed that Sox9 is expressed in mesenchymal tis-
sue of the out flow tract and endocardial cushions of the
heart chick embryos between days 3.5 and 4.5 of incuba-
tion. In the following stages its expression in these struc-
tures increases and reaches the atrioventricular sulcus. By
day 7 of incubation, transcripts are concentrated in the an-
lage of the valve leaflets and in the membranous portion
of the interventricular septum. From day 8, expression is
restricted to the connective portion of the atrioventricular
and arterial valve leaflets. Sox8 and Sox10 are detectable
in subendothelial mesenchyme, while Sox9 is present in
the whole core of the developing valves (Montero et al.,
2002).
Testicle
Since the discovery of Sox9 mutations in CD, concurrently
with studies concerning skeletal development, Sox9 has
been investigating for its role in sex determination.
In mammals, the presence of Y chromosome led the
bipotential gonad to differentiate in testicle (Barrionuevo
and Scherer 2010). Sertoli cells development is the first
sign of testis differentiation and represents a critical event
in male sex determination ( Jakob and Lovell-Badge,
2011). Experimental studies reducing or repressing Sox9
function, showed that Sox9 plays a key role in Sertoli cells
differentiation during testis development. Two-thirds of
patients affected by CD exhibit varying degrees of XY
male-to-female sex-reversal, whereas Sox9 duplication is
related to human patients XX female-to-male sex-reversal
(Pritchett et al., 2011). In XY Sox9-/- mice, Sertoli cells
do not develop, and thus no testis cord; whereas condi-
tional deletion of Sox9 in the gonad can result in XY male-
to-female sex reversal ( Jakob and Lovell-Badge, 2011).
During foetal development Sox9 is found in both male
and female gonads; gradually its expression becomes up-
regulated in male gonad and decreases till silencing in the
female one (Kent et al., 1996; Morais da Silva et al., 1996).
In developing gonad, SRY stimulates Sox9 expression for
Sertoli cells differentiation in a restricted time window: in
mouse between 10.75 and 12.5 days after coitus. It was
demonstrated that SRY has to act by this critical time or
Sox9 levels stay low and ovary development follows (Hi-
ramatsu et al., 2009). SRY activates Sox9 working in com-
bination with Steroidogenic factor-1 (SF1) via the
Testis-Specific Enhancer of Sox9 (TES) (Sekido and
Lovell-Badge, 2008). TES has been recently identified as
a regulatory sequence responsible for specific Sox9 testis
expression; within TES, a more definite region, TESCO,
highly preserved between mouse, rat, dog and man was
found ( Jacob e Lovell-Badge, 2011). SF1 and SRY to-
gether upregulate Sox9 and then, with SF1 help, Sox9 also
binds to the enhancer to help maintaining its own expres-
sion after that of SRY has ceased (Sekido and Lovell-
Badge, 2008). Sox9 then activates other genes involved in
male sex determination (Kamaki and Kondoh, 2013): it
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9up regulates, i.e., the production of anti-muellerian hor-
mone (Mackay, 2000; Josso et al., 2001), secreted during
the embryonic development by Sertoli cells and promoting
the regression of the Muellerian ducts ( Josso et al., 1993). 
To maintain Sox9 expression at high levels in Sertoli
cells, two positive feedback loops have been identified. Ac-
cording to recent studies, it seems that fibroblast growth
factor 9 (FGF9) and FGF receptor 2 (FGFR2) may play
a part in Sox9 expression maintenance, as both mutant
mice FGF9-/- and FGFR2-/- show a XY male-to-female
sex reversal related to the absence of Sox9 signal. It has
been shown, however, that Sox9 itself is required for FGF9
expression, generating a positive feedback loop ( Jakob and
Lovell-Badge, 2011). Another positive feedback loop is
represented by a cell-intrinsic mechanism involving Sox9
itself together with SF1 ( Jakob and Lovell-Badge, 2011).
Moreover Sox9 promotes Prostaglandin D2 (PGD2) syn-
thesis and Sox8 activation, another SoxE gene, that seems
to have a reinforcing role for Sox9 and is involved in the
maintenance of testicular functions at later stage ( Jakob
and Lovell-Badge, 2011; Kamachi and Kondoh, 2013).
Prostate
Mammalian prostate originates from urogenital sinus, an
embryonal structure composed by an epithelial layer sur-
rounded by mesenchymal tissue. In mouse, prostate mor-
phogenesis begins at embryonic day 17.5, when epithelial
cells grow into mesenchyme to form buds (Thomsen et al.,
2008). Sox9 plays an important role in the early stages of
prostate development and it is found in cell nuclei of the
epithelial buds (Thomsen et al., 2008). Prostate develop-
ment is androgen dependant with the initial androgenic
effects occurring through mesenchymal-dependent FGF
signalling (Huang et al., 2012), similarly to testis develop-
ment. Deletion of FGFR2 and Sox9 in mice show com-
parable prostate defects, suggesting that these genes and
their products are both necessary for early prostate devel-
opment (Thomsen et al., 2008). A prostate specific dele-
tion of Sox9 showed a lack in ventral prostate development
and an abnormal anterior prostate differentiation (Thom-
sen et al., 2008). Sox9 is needed not only for ventral lobe
development, where it regulates cellular proliferation and
differentiation, but even for adult prostate regeneration
(Huang et al., 2012).
Skin and hair follicle
Sox9 role in hair follicle (HF) development has been de-
scribed first by Vidal et al., (2005), that demonstrated Sox9
expression in the developing hair placode at embryonal day
(E) 14.5 and at E 12.5 in whisker pads of mice embryos
by in situ hybridization analysis . Sox9 was detected in the
thickening epithelial tissue but was absent in the underly-
ing mesenchyme. At E18.5 its expression is restricted to
the presumptive outer root sheet (ORS) layer. Sox9 ex-
pression was present at all stages of hair cycling but, at tel-
ogen stage positive Sox9 cells are detected at the base of
the hair-follicle epithelium, presumably representing the
bulge compartment (Vidal et al., 2005). The bulge is a part
of the ORS and represents a highly specialized hair follicle
niche that preserves the proliferative potential of quiescent
adult stem cell (Nowak et al., 2008). 
To evaluate the role of Sox9 in hair formation, trans-
genic mice with a skin-specific inactivation of Sox9 were
employed [Y10:Cre/Sox9(fl/fl)]. Sox9 knock-out mice
showed severe hair abnormalities, appeared hairless in the
caudal part of the body, defects in hair development and
hair follicle stem cells disappearance (Vidal et al., 2005).
Despite the nude appearance of Sox9 knockout mice, care-
ful observation demonstrated the presence of small, at-
rophic hair (Vidal et al., 2005). Histological alterations are
detectable from day 8 after birth with increased cellularity
in the dermis, and a decreased number of bulb matrix cells.
Absence of CD34 positive cells and reduction of cytoker-
atin 15 (K15) cells, both stem cells markers, are indicative
of bulge absence. These results indicated a role for Sox9 in
hair follicle maintenance, especially for the formation of
the bulge and for stem cells maintenance (Vidal et al.,
2005). Sox9, indeed, besides to be essential for outer root
sheath differentiation and the formation of hair stem cell
compartment itself (Vidal et al., 2005), it is expressed in
epithelial stem cells in mouse and human adult hair follicle
(Nowak et al., 2008).
Further studies allowed to understand that Sox9 is not
expressed throughout the early placode, but rather taking
over in the later stages and exclusively in a small subset of
supra-basal cells that do not correspond to the basal layer
expressing Lhx2, another transcription factor involved in
bulge formation. These two distinct populations of placode
cells may have distinct roles during HF morphogenesis;
Lhx2 participate in early events and disappears by about 7
days after birth (P7), while Sox9 takes over in the later
stages and gives rise to a long-lived stem cell population
with several essential functions, one of which is the com-
pletion of hair follicle morphogenesis (Nowak et al., 2008,
Christiano, 2008). The initial matrix cells are Sox9 nega-
tive: that is why in K14- Cre;Sox9flox/flox mice employed
for this study the early stages of hair follicle morphogen-
esis are preserved; and this explains also why they undergo
arrested development when Sox9-positive matrix cells
should replace the Lhx2-positive cells at �P7 (Nowak et al.,
The SOX family
10
2008, Christiano, 2008). Notably, this is the same time
point at which Vidal et al., (2005) reported the initial signs
of hair follicle degeneration in their mice, beginning with
a depletion of matrix cells in Y10:Cre;Sox9flox/flox mu-
tant animals.
In Nowak et al. (2008) study , authors demonstrated
that hair follicle Sox9 positive cells and their progeny do
not contribute to interfollicular epidermis either during
its development or its subsequent homeostasis. However
these cell are robustly recruited in case of a wound re-
sponse. In Sox9 cKO mice indeed, interfollicular epider-
mis regeneration is highly impaired (Nowak et al., 2008;
Christiano, 2008).
In subsequent studies, Sox9 expression in the skin has
been detected in the sebaceous gland, sweat gland, outer
root sheath of the hair follicles (Vidal et al., 2008; Shi et
al., 2013) and in the bulge (Vidal et al., 2008). Differently
from what observed in mouse, in human Sox9 is expressed
in keratinocytes basal layer too. Overexpression of Sox9
promotes human keratinocyte proliferation and inhibits
keratinocyte differentiation (Shi et al., 2013).
To conclude, it has emerged that the hair follicle rep-
resents an important stem cell reservoir in the skin, both
for epithelial stem cell (Vidal et al., 2008; Shi et al., 2013)
and for mesenchymal stem cell (Mercati et al., 2009), to
maintain tissue homeostasis and contribute to wound
healing processes (Nowak et al., 2008). Sox9 is expressed
in epithelial stem cells in adult hair follicle, that give rise
to all epithelial cells of the hair follicle, the sebaceous
gland, and the interfollicular epidermis (Christiano, 2008).
Mammary gland
The transcription factor Sox9 plays an important role in
mammary gland development. Most of the studies have
been performed in mice and human beings (Guo et al.,
2012a; Malhotra et al., 2014; Ye et al., 2015; Fazilaty et
al., 2015; Pomp et al., 2015). Conditional Sox9 deletion
results in defective mammary gland development with
substantial delay in ductal elongation and branching (Mal-
hotra et al., 2014). A study performed on Sox9 cKO mice
revealed that Sox9 deletion resulted in defects that were
particularly severe 3 weeks postnatal and were followed by
gradual recovery, with essential no defects beyond 8 weeks
of age. Recovery from this transient branching block im-
posed by Sox9 deletion seems to be related to the expan-
sion of mammary epithelial cells in which Sox9 deletion
did not occur. Moreover, in the same study, fate mapping
of Sox9 deleted cells demonstrated that Sox9 is essential
for luminal, but not myoepithelial, lineage commitment
and proliferation (Malhotra et al., 2014).
Mammary gland represents a useful model to study ep-
ithelial staminal cells, as it contains a subpopulation of
multipotent mammary stem cells (MaSCs) in the adult
mammary gland, with a remarkable regeneration capacity
(Guo et al., 2012a; Malhotra et al., 2014). It has been
demonstrated that Sox9 and Slug serve as a master regu-
lators of the gland-reconstituting activity of normal mam-
mary stem cells (Ye et al., 2015). 
In healthy mammary gland, indeed, Sox9 and Slug,
through epithelial to mesenchymal transition (EMT)
mechanisms, cooperate reprograming differentiated lumi-
nal cells of the mammary gland into MaSCs (Guo et al.,
2012a; Ye et al., 2015; Pomp et al., 2015), while Sox9 alone
converted these cells into luminal progenitors (Guo et al.,
2012a; Malhotra et al., 2014). Mature mammary luminal
cells expressing both Sox9 and Slug were able to activate
in adult MaSCs an endogenous autoregulatory network
and are capable of generating an entire mammary ductal
tree when transplanted into a mammary fat pad (Guo et
al., 2012a; Sarkar and Hochedlinger, 2013). In recent years
identification and characterization of molecular controls
that regulate MaSCs and progenitor cells homeostasis are
critical to our understanding of normal mammary gland
development and its pathology, neoplastic lesions included.
Up to now there are few studies concerning this issue, and
most of them are about Sox9 role in human brest carci-
noma (Guo et al., 2012a; Ye et al., 2015; Pomp et al.,
2015).
Sox9 in acquired diseases
Fibrosis and related disorders
As Sox9 plays multiple roles in embryogenesis and in con-
trol of proliferation and cell differentiation, it seems logical
that its inappropriate or ectopic expression can result in
disease (Pritchett et al., 2011). Sox9 implication in fibro-
sis-related disorders and even in neoplastic cells growth
have been investigated (Akiyama, 2008). Ectopic Sox9 ex-
pression indeed mediates extracellular matrix (ECM) dep-
osition (Piper-Hanley et al., 2008): fibrosis, sclerosis and
related disorders can affect virtually all tissues and organs
in the body and characterize several chronic diseases. They
are characterized by excessive, inappropriate ECM depo-
sition, resulting in the destruction of tissue architecture
and function (Pritchett et al., 2011).
Type1 collagen is the major collagen subtype deposited
Role of the transcription factor SOX9 in the tumorigenesis of some domestic animal neoplasms
11
in organ fibrosis and its levels increase with Sox9 level
growth (Piper-Hanley et al., 2008). Transforming growth
factor β (TGF-β ) and fibroblast growth factor 2 (FGF2)
seems to augment ECM deposition, increasing Sox9 ex-
pression (Piper-Hanley et al., 2008), even if a recent study
suggests that is Hedgehog signaling, not TGF-β, that lies
upstream of Sox9 ( Jo et al., 2014). Anyway, both TGF-β
and FGF2, together with other transcription factors as
Slug, promote epithelial-to-mesenchymal transition
(EMT), converting normal and neoplastic epithelial cells
into derivatives with a more mesenchymal phenotype
(Piper-Hanley et al., 2008; Riemenschnitter et al., 2013).
Through EMT indeed, cells lose epithelial markers as Cy-
tokeratins and E-Cadherin, and gain mesenchymal mark-
ers as Vimentin, a-Sm Actin (Pritchett et al., 2011). In
development, this process induces Sox9 expression during
neural crest delamination for (i.e) the differentiation of
chondrocytes and astrocytes ( Jo et al., 2014). EMT is also
a forerunner of organ fibrosis when the resultant mes-
enchymal cells express abundant type1 collagen as part of
the fibrotic matrix (Piper-Hanley et al., 2008). Sox9 results
overexpressed in glomerulosclerosis, vascular calcification,
hepatic, and cardiac fibrosis (Piper-Hanley et al., 2008;
Pritchett et al., 2011). In particular, in kidney with
glomerulosclerosis, high expressions of Osteopontin and
other TGF-β genes were observed, suggesting that Sox9
activity is similar in both glomerulosclerosis and liver fi-
brosis ( Jo et al., 2014).
Tumors
Sox9, as emerged from the previous section, together with
other transcription factors as Slug, is involved in EMT, an
early developmental phenomenon that results in the ac-
quisition of an invasive, mesenchymal phenotype by ep-
ithelial cells (Riemenschnitter et al., 2013). In the context
of neoplasia, passage through an EMT results in the ac-
quisition of cell-biological traits associated with high grade
malignancy, including motility, invasiveness and increased
resistance to apoptosis (Guo et al., 2012a,b).
With respect to neoplasms, Sox9 has been identified as
a pro-oncogenetic factor in a wide range of human tumors;
where it is overexpressed promotes cellular proliferation,
bypasses senescence and it is able to immortalize primary
stem cells (Matheu et al., 2012). On the other hand, as for
some human and mice melanomas, Sox9 is likely to oper-
ate as tumor suppressor (Passeron et al., 2009; Matheu et
al., 2012). These data present opposing roles for Sox9 in
tumors, either inducing or potentially inhibiting cell pro-
liferation. The differences between these studies could be
attributed, in part, to the differences in cell lines and levels
of Sox9 ( Jo et al., 2014). Anyway in recent studies Sox9
has found to be overexpressed in most of human neoplastic
cell lines, with the exception of lymphomas and kidney
cancers (Matheu et al., 2012). There are strong analogies
between normal tissue stem cells and tumor-initiating cells
(TICs): for this reason some researchers proposed a com-
mon activation program (Ye et al., 2015). TICs seem to be
responsible for both initiating the bulk of tumors and in-
creasing cell migratory and invasive properties, a prereq-
uisite for tumor metastasis (Luanpitpong et al., 2015; Ye
et al., 2015). This is confirmed by the observation that the
presence of TICs in primary tumors is strongly correlated
with an increased incidence of metastasis and poor survival
of patients (Luanpitpong et al., 2015).
Sox9 role in human cancer is context dependent and
related to the transcription factors involved (Matheu et al.,
2012). Slug (also known as Snai1) and Snail (or Snai2) are
members of the Snail family of the EMT-inducing tran-
scription factors. These transcription factors induce distinct
EMT programs (Ye et al., 2015).
Slug and Sox9 determine the mammary stem cell
(MaSC) state, and work as regulators of the gland-recon-
stituting activity of normal MaSCs (Guo et al., 2012a; Ye
et al., 2015).
On the other hand, the induction of differentiated lu-
minal epithelial cells into cancer cells exhibiting basal fea-
tures is tightly associated with EMT activation with Snail
participation. Shutdown of Snail, indeed, could selectively
eliminate breast TICs (Ye et al., 2015).
This argument is still debated; in literature different and
often contrasting results are reported, as this issue is still
evolving. Forced expression of Slug in collaboration with
Sox9 in several solid tumors was found to promote the for-
mation of tumor-initiating cells (TICs) formation, but it
is not required for EMT activation in lung cancer cells
(Luanpitpong et al., 2015; Ye et al., 2015).
Previous works correlated high levels of Slug to poor
prognosis in brest or lung cancer neoplasms (Guo et al.,
2012a; Luanpitpong et al., 2015) but the prognostic power
of Slug expression may be due in large part to its strong
association with basal differentiation, which is, on its own,
a well-known feature of aggressive breast cancers (Ye et
al., 2015).
Knockdown of Slug and Sox9 repressed TICs, in
agreement with the previous report implicating their role
in breast tumor initiation, and inhibited experimental
metastasis, which is likely due to their effect on TICs and
not on the EMT process, as EMT remained activated after
Slug knockdown (Luanpitpong et al., 2015).
Sox9 positive cancer cells are often detected in tissues
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where Sox9 plays critical roles in their development and
within the stem cell compartments of most of the corre-
sponding normal tissues (Matheu et al., 2012), such as
lung (Zhu et al., 2012), gastrointestinal tract (Lu et al.,
2008; Kimura et al., 2011; Matheu et al., 2012; Sun et al.,
2012) prostate (Wang et al.,2007; Huang et al., 2012),
mammary gland (Chakravarty et al., 2011a) or hair follicle
(Shi et al., 2013).
The high levels of Sox9 detected in some neoplasms
might reflect the origin of the tumors from the expansion
of Sox9-positive stem/progenitor cells. Activated stem
cells indeed are required for injury repair, and chronic in-
jury increases the risk of forming cancer (Pritchett at al.,
2011). Together with a transforming agent, activated
oncogene, or event such as chronic injury, higher levels of
Sox9 significantly increase the rate of developing tumors
(Matheu et al., 2012).
On the other hand, Sox9 seems to be expressed even
in tissues where Sox9 is not known to be involved during
normal physiology (Matheu et al., 2012).
Sox9 detection potentially carries prognostic value in
a range of tumors including neurofibromatoma, medul-
loblastoma, colon cancer and prostate cancer. Although
the identification, validation and application of biomarkers
is complex, it has been suggested that immunostaining for
Sox9 in biopsy samples and pathology resections could aid
diagnosis and prognostication for patients (Pritchett at al.,
2011). Sox9 expression in human breast cancer or in lung
adenocarcinoma, i.e., is associated with tumor progression
and malignancy (Chaktravarty et al., 2011a; Zhu et al.,
2012).
In lung cancer Sox genes seem to have an oncogenic
potential; overexpression of Sox9 indeed seems to promote
lung adenocarcinoma cell proliferation (Zhu et al., 2012),
TICs and metastases in a mouse model (Luanpitpong et
al., 2015). In lung metastatic tumor cells, increased Slug
expression stabilizes Sox9, inhibiting Sox9 ubiquitination
and proteosomal degradation. Sox9 stabilization promotes
the expansion of TICs and subsequent cancer metastasis
(Luanpitpong et al., 2015).
Sox9 seems to be required for prostate carcinogenesis
in animal models (Huang et al., 2012), but it has been
found even in primary prostate cancer in vivo, at a higher
frequency in recurrent prostate cancer and in prostate can-
cer cellular lines too (Wang et al., 2007). It is possible that
Sox9 transactivates the androgen receptor, as some
prostate cancers are androgen-dependent. On the other
hand, one study showed that Sox9 suppresses growth and
tumorigenesis in the prostate tumor cell line M12 ( Jo et
al., 2014).
In pancreas Sox9 is detected in all types of pancreatic
lesions/neoplasms of ductal origin, but rarely in other pan-
creas neoplasms, representing a useful marker for the ep-
ithelial cells of pancreatic ductal system, including
centroacinar cells, and for the ductal lineage of pancreatic
neoplasms (Shroff et al., 2014). Sox9 moreover accelerates
the formation of precursor lesions of pancreatic ductal ade-
nocarcinoma ( Jo et al., 2014). It was moreover reported
that the Sox9 expression was decreased in pancreatic in-
traepithelial neoplasia and increased in pancreatic ductal
adenocarcinoma (Matsuhima et al., 2015). As explained
earlier, Sox9 as a biomarker may be helpful in im-
munophenotype detection, to better asses the tissutal ori-
gin of the neoplasm, as in case of hair follicle, neural crest
or cartilagineous neoplasms (Wehrly et al., 2003; Vidal et
al., 2008; Carbonelle-Puscian et al., 2011). Sox9 indeed
has been employed to distinguish mesenchymal chon-
drosarcoma from other small blue round cell tumors,
whose therapy and prognosis differ considerably (Wehrly
et al., 2003). Sox9 is detected in benign cartilagineous neo-
plasms as chondromyxoid fibroma and chondroblastoma
and may be useful for differential diagnosis of these tumors
(Dancer et al., 2010) A recent study demonstrated that
downregulation of Sox9 could inhibit migration and in-
vasion of chondrosarcoma cells (Li et al., 2015).
With regard to liver, SRY and in particular Sox9 is ex-
pressed in hepatocellular carcinoma and the nuclear ex-
pression of SRY is associated with cancer progression and
poor patient survival (Xue et al., 2015). In cases of intra-
hepatic cholangiocarcinoma a two-stage patterns of Sox9
expression has been observed: the first one with Sox9 ex-
pression decreasing, related to the early stage of the car-
cinogenesis, and the second with Sox9 increase due to
biliary infiltration and poorer prognosis, promoting cell
migration and invasion (Matsushima et al., 2015). This ex-
pression pattern has been observed for pancreatic ductal
adenocarcinoma and gastric carcinoma too (Sun et al.,
2012; Matsushima et al., 2015). Sox9 upregulation in car-
cinogenesis of the digestive system have been detected in
esophageal squamous cell carcinoma (Hong et al., 2015),
gastric cancer (Sun et al., 2012) and colorectal cancer
(Shen et al., 2015).
Regarding colon carcinoma, Sox9 induces the expres-
sion of S-100P, a protein related to proliferation, tumori-
genesis regulation, invasion and cancer cell motility,
leading to increased cell invasiveness and metastasis as well
as activation of EMT (Shen et al., 2015). As previously
explained, the Wnt signaling pathway, together with Sox9,
is crucial for crypts and Paneth cells maintenance: Wnt
activating mutations are often found in colorectal cancers;
the same happens for members of other developmental
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programs as Notch or bone morphogenetic proteins, tran-
scription factors involved with Sox9 in developmental
processes of various tissues (Matheu et al. 2012). Sox9 is
overexpressed in colorectal cancers; given the role of Sox9
in stem cells in the intestinal epithelium, the high levels
of Sox9 might reflect the origin of the tumors from trans-
formation of such cells. Alternatively, the high levels of
Sox9 could reflect a loss of repression, or genetic alterations
and/or other types of deregulation (Matheu et al. 2012).
In addition Sox9 regulates B lymphoma Mo-MLV inser-
tion region 1 (BMI1) expression, a well-established onco-
gene; their interactions are likely to be critical events in
colorectal tumor development and progression. Sox9 and
BMI1, cooperate in EMT, leading to cancer metastasis
that occurs in the most advanced colorectal cancers
(Matheu et al. 2012).
Skin and hair follicle neoplasms, mammary gland neo-
plasms, nervous tissue development and neoplasms are dis-
cussed in the following sections.
The SOX family
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In veterinary literature there is few data concerning the
role of Sox9, and most of them concern its role in gonadal
development. Sox9 sequence in dog shows high homology
to other Sox9 genes, since it is highly conserved among
vertebrates. Similarly, Sox9 expression is implicated in ca-
nine testis determination. The pattern and timing of canine
gonadal Sox9 expression is similar to those described for
humans, pigs, goats, and mice (Meyers-Wallen, 2003) and
it has been previously described. Sox9 has been investi-
gated in cases of XX sex reversal syndrome, the most com-
mon form of intersexuality occurring in dogs, where
testicular tissue develops in the absence of the key gene,
SRY (Groppetti et al., 2012). This abnormality of gonadal
sex determination is observed in human too, where at
about 80% of XX sex reversed patients show a SRY
translocation. The remaining 20% do not have SRY or any
other genes normally located on the Y chromosome (Mey-
ers-Wallen, 2006). As for human XX reverse syndrome,
even in dog has been recently demonstrated the role of
Sox9 duplication in the development of this anomaly
(Rossi et al., 2014; Xiao 2013).
Other researches focused on stem cells demonstrated
that canine mesenchymal stem cells, treated with suitable
induction media, differentiate in chondrocytes exhibiting
Sox9 transcription factor (Csaki et al., 2007). Sox9 positive
stem cells have been identified in canine hair follicle bulge
too (Kobayashi et al., 2010). From this study has emerged
that canine staminal cells localization in the hair follicle
matches the human one. In anagen canine primary hair
follicles, indeed, multipotent cells were predominantly ob-
served in the outermost layer of the outer root sheet (ORS)
around a little bud that provides the insertion point of the
erector pili muscle. In the same study, canine anagen hair
follicles were microdissected into four fragments: P1
(bulb), P2 (suprabulbar), P3 (isthmus including bulge), and
P4 (infundibulum). Genes crucial for the development and
maintenance of mouse bulge stem cells like Sox9, Lhx2,
Tcf3, and Nfatc1 were tested by means of real-time PCR;
all of these genes were over-represented in P3 from dogs
and human. Sox9 especially was the most evident. Thus,
canine bulge cells share some crucial gene expression pro-
files with mouse and human bulge stem cells (Kobayashi
et al., 2010).
SOX9 in normal tissues of various ani-
mal species
The results of a preliminary evaluation of Sox9 antibody
used in the research studies of this thesis are shown
below. The evaluation has been performed on tissues and
organs of various animal species. 
Anti-Sox9 antibody employed is a rabbit polyclonal
serum (Sigma-Aldrich, St. Louis, MO, USA) obtained
using a 117 amino-acids peptide corresponding to the N-
terminal of human Sox9. This peptide sequence has been
compared with the one of various domestic animals and it
resulted highly conserved (table 1).
To assess the immunohistochemical staining for this
marker serial diluition tests have been performed on sev-
eral organs of different animal species (table 2).
Internal positive controls were represented by skin and
hair follicle adnexa. Sox9 immunolabeling was scored as
negative (-), weak (+), moderate (++), intense (+++). NP=
not present. Sox9 expression was detected in many domes-
SOX9 in veterinary medicine
Table 1. Sox9 sequence identities and similarities in various an-
imal species.
Specie
Identities
(%)
Positive similarities
(%)
Cat
Felis catus 97 98
Dog
Canis familiaris 96 98
Goat
Capra hircus 89 95
Horse
Equus caballus 98 99
Swine
Sus scrofa 94 94
Cow
Bos taurus not reported not reported
Rabbit
Oryctolagus cunicoli not reported not reported
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Tissue Cat Cow Dog Goat Horse Rabbit Swine
CNS ++ ++ ++ ++ ++ + +
Forestomach NP + NP ++ NP NP NP
Heart - - - - - - -
Kidney - - - - - - -
Large Intestine + ++ + ++ + + +
Liver ++ +++ ++ +++ +++ ++ +
Lung + + + ++ +++ + +
Lymph node - - - - - - -
Mammary gland ++ ++ ++ ++ ++ NP NP
Pancreas +++ +++ +++ ++ +++ ++ +++
Salivary gland +++ ++ + ++ ++ + -
Skeletal muscle - - - - - - -
Skin +++ +++ +++ +++ +++ +++ +++
Small Intestine ++ ++ ++ +++ +++ ++ +++
Spleen - + - + - - +
Stomach + + + + + - +
Testicle ++ +++ +++ +++ +++ NP NP
Thyroid - - - - - - -
Table 2. Sox9 immunohistochemical results. Table legend:- = negative immunolabeling; + = weak, ++ = moderate, +++= intense
immunolabeling. NP= tissue not present.
Figure 1. Sox9 immunohistochemical results on canine hair follicle (A) (obj. 40 x), bovine liver (B) (obj. 20 x), goat pancreas (C)
(obj. 20 x) and testis (D) (obj. 10 x). Haematoxylin counterstain.
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tic animal tissues, but especially in the hair follicle and in
other skin adnexa (Fig. 1A), in bile ducts of the liver (Fig.
1B), in pancreas ductal component (Fig. 1C), in basal cells
of the seminiferous ducts of the testicle (Sertoli cells) (Fig.
1D) and in basal glandular cells of the small intestine (Fig.
2D). In lung, strong immunolabeling was detected in scat-
tered cells in bronchial cartilage and diffusely in bronchial
epithelium (Fig. 2A). In the spleen dendritic cells some-
times resulted mildly positive, as well as glandular cells in
the stomach. Sox9 positivity in the central nervous system
was detected in neuronal cytoplasm and in scattered glial
cells (Fig. 2B). Forestomach of ruminants showed mild to
moderate positivity in basal layers (Fig. 2C)
Figure 2. Sox9 immunohistochemical results on equine lung (A) (obj. 10 x), bovine central nervous system (B) (obj. 20 x), goat
forestomach (C) (obj. 20 x) and bovine small intestine (D) (obj. 20 x). Haematoxylin counterstain.
SOX9 in veterinary medicine
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Sox9 in canine epidermal skin tumors
Introduction
Sox9 in human is highly expressed in several skin diseases
as psoriasis or acne (Shi et al., 2013), and generally in ad-
nexal-related neoplasms (Vidal et al., 2008; Krahl and
Sellheyher, 2010a,b; Shi et al., 2013), basal cell carcinoma
(Vidal et al., 2008), squamous cell carcinoma (Shi et al.,
2013) and metastatic melanoma (Rao et al., 2010). The
role of Sox9 in skin tumorigenesis, however, needs to be
clarified yet (Shi et al., 2013).
Vidal et al., (2008) investigated the role of Sox9 in case
of human basal cell carcinoma (BCC); its expression was
observed in all subtypes of BCC tested and in all adnexal
skin tumors analyzed, suggesting a role for Sox9 to the
pathogenesis of these tumors. According to the authors,
the heterogeneous staining obtained may be related to
these tumors are composed of cells from various origins
and/or it might reflect the different status of the tumor
cells.
Further studies on human skin found that Sox9 expres-
sion in during cutaneous embryogenesis and post-natal
period strongly resembles the one observed in BCC and
in pilomatrixoma in their spatial distribution within the
various follicular subcompartments. Basaloid cells of pilo-
matricoma indeed are Sox-negative as the evolving hair
matrix of the embryonic hair follicle, while BCC cells re-
sulted positive, as the primordial outer root sheath (Krahl
and Sellheyer, 2010a). BCC is still viewed by many der-
matologists as originating from the interfollicular epider-
mis but there is an increasing body of evidence that links
this neoplasm to the hair follicle and classifies the tumor
as the most primitive follicular neoplasm. This study
strongly underline the existing link between the embryol-
ogy of the skin and the histogenesis of adnexal tumors: an
appropriate immunophenotyping may allow a different
classification of adnexal neoplasms (Krahl and Sellheyer,
2010b).
Among various specific human bulge markers that are
similarly overexpressed in canine bulge cells, Sox9 is one
of the most represented. Canine bulge stem cells, indeed,
strongly resemble distribution and biochemical features of
the human ones (Kobayashi et al., 2010). Some canine fol-
licular tumors show an expression of hair follicle stem cell
markers and it could be suggested that these positive cells,
having some features of stem cells, may play a role in
tumor development (Brachelente et al., 2013). The aim of
this study was to investigate the immunopositivity for
Sox9 in different canine epidermal and hair follicle neo-
plasms; differences in Sox9 expression would help to cor-
relate tumor phenotype with molecular characteristics thus
allowing to better define tumor development, contribute
to its diagnosis and clinical management.
Materials and Methods
Case selection
Different types of canine epithelial tumors were retrieved
from the files of the Department of Veterinary Medicine
of Milan. Samples of squamous papilloma (n=5), squa-
mous cell carcinoma (n=6), infundibular keratinizing acan-
thoma (n=4), inferior tricholemmoma (n=5), isthmic
tricholemmoma (n=2), trichoblastoma (n=12), trichoep-
ithelioma (n=7), malignant trichoepithelioma (n=3), pilo-
matricoma (n=2), subungual keratoacanthoma (n=1),
subungual squamous cell carcinoma (n=4) were selected.
Normal skin tissue surrounding the tumor was also in-
cluded in the study.
The diagnosis of each tumor was revised according to
the criteria of the World Health Organization classifica-
tion.
Immunohistochemical staining
Four-micrometer thick sections from routinely formalin-
fixed and paraffin-wax embedded samples were prepared
on poly-L-lysine-coated glass slides for immunohisto-
chemistry. The sections were de-paraffinized in xylene and
rehydrated through graded alcohols. Endogenous peroxi-
dase was blocked using 3% hydrogen peroxide in distilled
water for 5 min, then, antigen retrieval for formalin-fixed
samples was accomplished by microwave irradiation in cit-
SOX9 in the skin and hair follicle
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rate buffer, pH 6.0, for 10 min. Normal goat serum for 30
min was employed to block sections. Sections were then
incubated for 18 h at 4°C with anti-Sox9 rabbit polyclonal
antibody (HPA001758; Sigma-Aldrich, St. Louis, MO,
USA) diluted 1:200. The antibody recognizes a Sox9 spe-
cific peptide of 117 amino acids with 96% identity with
Canis familiaris. The sections were incubated for 30 min
with 1:200 goat anti-rabbit biotin conjugate antibody
(Vector Laboratories, Burlingame, CA, USA; BA 1000)
and subsequently stained for 30 min with streptavidin-bi-
otin peroxidase kit (Vectastain Elite ABC, Vector Labo-
ratories, PK-6100). Positive staining was visualized with
3.3-diaminobenzidine-4 HCl (Vectastain, Vector Labo-
ratories, SK-4100) and nuclei were counterstained with
Mayer’s hematoxylin. Sox9 reactivity of follicular outer
root sheath present in normal cutaneous tissue of tumor
Table 1. Immunohistochemical results
Neoplasm Case no.
Positive
cells
Signal
intensity
Global
Score
Squamous Papilloma #1 1 1 2
#2 3 2 5
#3 1 2 3
#4 2 2 4
#5 3 3 6
Squamous Cell
Carcinoma
#1 1 1 2
#2 3 2 5
#3 3 3 6
#4 1 1 2
#5 2 2 4
#6 2 1 3
Infundibular
Keratinizing
Acanthoma
#1 1 1 2
#2 2 2 4
#3 1 1 2
#4 4 3 7
Subungual
Keratoacanthoma #1 0 - 0
Subungual Squamous
Cell Carcinoma 
#1 2 2 4
#2 1 2 3
#3 1 1 2
#4 1 2 3
Inferior
Tricholemmoma
#1 3 3 6
#2 2 2 4
#3 2 1 3
#4 2 3 6
#5 4 3 7
Neoplasm Case no.
Positive
cells
Signal
intensity
Global
Score
Isthmic
Tricholemmoma
#1 3 3 6
#2 3 3 6
Trichoblastoma #1 4 3 7
#2 4 3 7
#3 4 3 7
#4 4 2 6
#5 4 3 7
#6 4 3 7
#7 3 3 6
#8 4 3 7
#9 3 3 6
#10 4 3 7
#11 4 1 5
#12 2 2 4
Trichoepithelioma #1 2 2 4
#2 4 3 7
#3 3 2 5
#4 3 3 6
#5 2 3 5
#6 1 2 3
#7 3 2 5
Malignant
Trichoepithelioma
#1 3 2 5
#2 3 2 5
#3 2 3 5
Pilomatricoma #1 3 2 5
#2 2 3 5
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sample was used as internal positive control. Negative con-
trol sections were produced by omission of the primary
antibody.
Evaluation of immunohistochemical data
The immunohistochemically stained tissue slides were ex-
amined using standard light microscopy. The staining re-
sults were independently scored by the authors as follows:
Sox9 protein expression was assessed by categorizing im-
munoreaction of each tumor cell type into four groups ac-
cording to the proportion of positive cells: 0, no positive
cells; 1, from 1% to 25% positive cells; 2, from 25% to 50%;
3, from 50% to 75%; 4, from 75% to 100%. The intensity
of labeling was graded as: W, weak positive staining; M,
moderate positive staining; I, intense positive staining, and
scored as follows: W=1, M=2, I=3. A global score was con-
ferred adding together the positive cells percentage score
and the intensity of immunolabeling score.
Results
Sox9 immunohistochemical results are reported in table
1.
In every section a portion of healthy skin next to the
neoplasms was always included, as Sox9 internal positive
tissue control (Fig. 1A). Immunohistochemical examina-
tion resulted always positive. In normal skin, Sox9 positive
reaction was restricted to the bulge region and outer root
sheath of the hair follicles and to germinative cells of se-
baceous glands. Well differentiated sebocytes, sweat glands
and epidermal cells were mostly negative. Only in a few
cases Sox9 positive epithelial cells were present in basal
and spinous layers of hyperplastic, reactive epidermis near
and above the neoplastic tissue.
Squamous papilloma
In 4 of 5 squamous papillomas the number of Sox9 posi-
tive cells varied from 1-25% (1 case) to 25-50% (1 case),
or 50-75% (2 cases) showing moderate to intense im-
munolabeling, staining especially basal and suprabasal
cells. Only in 1 case, the percentage of Sox9 positive cells
ranged from 1% to 25% and appeared weakly positive.
Squamous cell carcinoma
Sox9 was positive in all 6 squamous cell carcinomas (Fig.
1B), with a variable number of positive cells, extending
from 1-25% (2 cases) to 25-50% (2 cases) or 50-75% (2
cases). The intensity of staining being intense in 1 case,
Figure 1. Sox9 immunohistochemistry. A: Hair follicle positive control: transverse sections with various positive nuclei. B: Squa-
mous cell carcinoma. Intense, diffuse, irregular nuclear positivity in neoplastic cells with basal and spinous differentiation (aster-
isks). Positive cells are also detected in reactive fibrous stroma. C: Trichoblastoma. Cords and spirals of neoplastic epithelial cells
almost entirely positive for Sox9. D: Trichoepithelioma. Abundant keratin (asterisk) surrounded by basal and suprabasal epithelial
cells intensely positive (arrows). E: Pilomatricoma. Wall of a neoplastic cyst with positive cells mostly in superficial layers. F: Sub-
ungual squamous cell carcinoma with scatterd positive spinous cells (A, C, D Bar= 75 μm; B, F, E Bar = 150 μm).
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moderate in 2, weak in 3. Immunolabeling involved espe-
cially basal cell layer and spinous cells, even if in 3 cases
its distribution was very irregular.
Infundibular keratinizing acanthoma
Sox9 showed a variable positivity: in all 4 cases, ranging
from a rare and weak staining (2 cases) to a diffuse and in-
tense immunolabeling (1 case).
Inferior tricholemmoma
Sox9 showed a variable positivity in all 5 tricholemmoma
cases. The number of positive cells usually ranged from
25% to 50% (3 cases), with intensity of staining from weak
to intense. Two tumors were diffusely (50-100% of positive
cells) and strongly positive.
Isthmic tricholemmoma
In both isthmic tricholemmomas, positive cells varied from
50% to 75% of neoplastic cells. An intense immunolabel-
ing was detected and involved mainly peripheral basal
cells.
Trichoblastoma
All 12 trichoblastoma (Fig. 1C) were Sox9 positive; 9 tu-
mors were diffusely positive (75-100% of neoplastic cells
in 7 cases, 50-75% in 2 cases) with an intense staining,
whereas in 1 case Sox9 showed diffuse (75-100% of cells)
but weak, immunolabeling. In 2 cases there was a variable
percentage of positive cells (from 25% to 100%) with a
moderate intensity of staining.
Trichoepithelioma
Four of 7 trichoepitheliomas (Fig. 1D) showed a very wide
percentage of positive cells, ranging from 1-25% to 75%;
Sox9 immunolabeling was moderate. In 3 cases, 25-50%
to 75-100% of the tumor cells showed an intense staining.
Sox9 was detected mainly in peripheral basal cells and in
suprabasal cells with spinous differentiation. Only in 1 case
a rare and weak immunolabeling was observed.
Malignant trichoepithelioma
All 3 tumors expressed Sox9. The percentage of positive
cells varied from 25-50% (1 case) to 75-100% (2 cases).
The intensity was usually moderate (2 cases) or intense (1
case). Peripheral basal cells and suprabasal cells were
mostly positive.
Pilomatricoma
The 2 tumors expressed from 25% to 75% of positive cells,
with a moderate to intense Sox9 positivity (Fig. 1E).
Subungual keratoacanthoma
Sox9 was negative in neoplastic keratoacanthoma cells. In-
ternal control, represented by normal skin hair follicles,
was mildly positive.
Subungual squamous cell carcinoma
The percentage of positive cells in subungual squamous
cell carcinomas (Figure 1 F) ranged from 1-25% (3 cases)
to 25-50% (1 case) of positive cells. The intensity of im-
munolabeling varied from weak (1 case) to moderate (3
cases), especially in spinous and basal layer. Immunolabel-
ing decreased or disappeared in most differentiated cells.
Discussion
Genes involved in developmental processes or tissue
homeostasis maintenance are often overexpressed in tu-
morigenesis (Vidal et al., 2008; Matheu et al., 2012). Sox9
is implicated in a wide range of human neoplasms, espe-
cially in organs where it plays a role in their developmental
stages and in stem cells maintenance (Vidal et al., 2008;
Matheu et al., 2012), but it has been found even in other
neoplasms, as fibrosarcomas, where Sox9 is not known to
be required during normal physiology (Matheu et al.,
2012). 
As regards skin, Sox9 is present in the outer root sheet
of human hair follicle and sebaceous gland, especially in
basal layers; Sox9 has been also detected in basal layer of
inter-follicular epidermis too (Shi et al., 2013). In canine
normal skin, Sox9 positive cell distribution was similar to
that reported in man (Vidal et al., 2008; Krahl and Sell-
heyer, 2010b). In a few cases scattered Sox9 positive ep-
ithelial cells were detected also in upper hyperplastic
epidermis above the neoplastic tissue; similar findings have
been described in man by Vidal et al. (2008) and Shi et al.
(2013).
This gene, indeed, is required for the specification of
early bulge cells and its progeny; moreover it is responsible
of maintenance of stem cells characteristics in the adult
bulge niche, whose action is necessary in a wound envi-
ronment (Nowak et al., 2008).
As previously described by some Authors (Nowak et
al., 2008; Krahl and Sellheyer, 2010b), various cutaneous
neoplasms mirror some of Sox9 embryological expression
patterns, sometimes even reflecting its spatial distribution
within the various follicular subcompartments (Krahl and
Sellheyer, 2010a,b).
Sox9 was detected in all the adnexal tumors tested, with
the exception of subungual keratoacanthoma, maybe due
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to its origin from the nailbed epithelium (Goldschmidt et
al., 1998). Subungual squamous cell carcinomas resulted
moderately positive. As for subungual keratoacanthoma,
the origin from a highly differentiated epithelium could
explain the reduced Sox9 expression as well as the loss of
other stem cell markers (Brachelente et al., 2013). Sox9
expression in epidermal keratinocytes indeed, is promi-
nently detected in undifferentiated rather than in differ-
entiated keratinocytes (Shi et al., 2013).
Sox9 was expressed at the highest levels in neoplasms
strictly related to embryonal hair follicle, as trichoblas-
tomas. Both in human and veterinary medicine trichoblas-
tomas are considered to be neoplasms deriving from hair
follicle stem cells (Hurt et al., 2006); our findings therefore
support this hypothesis and confirm the results of other
studies performed in dogs employing different stem cell
markers (Pascucci et al., 2006; Mercati et al., 2008;
Brachelente et al., 2013). The intensity of immunolabeling
and number of Sox9 positive cells may be related to the
cycling and bulge-harboring portion of the follicle, respec-
tively represented by the hair stem and the isthmus (Krahl
and Sellheyer, 2010b).
Sox9 immunolabeling was observed in high percentage
of cells also in tricholemmomas and trichoepitheliomas
especially in peripheral basal cells and in less differentiated
suprabasal cells. Regarding trichoepithelioma, the hetero-
geneity in Sox9 staining may reflect the origin of this neo-
plasm from the three different parts of the hair follicle
(Goldschmidt et al., 1998; Brachelente et al., 2013). Ma-
lignant trichoepitheliomas, in lesser extent, show the same
immunolabeling variability.
Tricholemmomas, both inferior and isthmic type,
showed a variable positivity especially in basal and
suprabasal layers, but no relevant differences in immuno-
histochemical reactivity were observed. There is no general
agreement about the origin of these neoplasms; they are
supposed to derive respectively from the inferior segment
of the outer root sheet or from the isthmus segment of the
outer root sheet; experimental data are rather controversial
(Vidal et al., 2008; Brachelente et al., 2013). Squamous
cell carcinomas, both epidermal and subungual type, and
squamous papillomas expressed Sox9 with various degrees
of positivity. Squamous cell carcinoma was irregularly Sox9
positive in accordance with previous studies where differ-
ent markers for stem cells were considered (Sellheyer,
2011; Bongiovanni et al., 2011; Shi et al., 2013).
Sox9 expression patterns in pilomatricomas resemble
those of the developing and the post-natal hair follicle
(Krahl and Sellheyer 2010a,b). In the current study, ac-
cording with the previous work by Krahl and Sellheyer,
(2010b) basaloid cells/bulb germ cells were Sox9 negative,
while a Sox9 positivity was observed in more differentiated
cells. These neoplasms, therefore, have to be considered as
trichoepitheliomas with a prominent matrical component. 
In recent years many efforts have been made to find a
logical classification of adnexal tumors according to a new
molecular-morphological characterization, investigating
neoplasm stem cell biology (Sellheyer, 2011). Regarding
canine tumors, the association between hair follicle and
various stem cell markers, as CD34, CK15 and Nestin,
have been investigated (Pascucci et al., 2006; Mercati et
al., 2008; Brachelente et al., 2013), each with its own char-
acteristics feature and target. Sox9 may be proposed as an-
other reliable stem cell marker for dermopathologists to
better assess the role of stem cells in canine epidermal and
follicular tumors.
SOX9 in the skin and hair follicle
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expression during testis formation and adulthood parallels
humans (de Santa Barbara et al., 2000; Kobayashi et al.,
2005; Nel-Themaat et al., 2011). On the other hand, in
rats, Sox9 protein expression seems to be dependent on
the age and stage of spermatogenesis: prominently ex-
pressed in gonadal blastemal of embryonic testis, Sox9
gradually declines in postnatal gonads but strongly reoc-
curs in pubertal and adult testis (Frojdman et al., 2000;
Pelliniemi and Frojdman, 2001).
Regarding other animal species, data are relatively
scarce and mainly focused on embryonal gonads (Car-
mona et al., 2009; Elzaiat et al., 2014). Concerning canine
species, a polymerase chain reaction–based study investi-
gated the expression of Sox9, both in female and male em-
bryos from 27 to 37 days of gestation. Sox9 was found to
be expressed in the urogenital ridge, in both sexes up to
Day 30 of gestation, and then it becomes markedly ele-
vated only in male gonads with little or no expression in
other components of the urogenital ridge. Authors con-
cluded that these findings similarly to those reported for
humans and other domestic animals were consistent with
the role of Sox9 in testis determination (Meyers-Wallen,
2003).
Nevertheless, besides its critical role in testicular deter-
mination and different timing of expression among
species, the physiological relevance of Sox9 in adult testes
and its possible role in the neoplastic counterpart deserve
further investigation.
As a gene related to cellular proliferation and differen-
tiation, Sox9 protein induction and its implication in the
growth of neoplastic cells and extracellular matrix depo-
sition has been recently considered (Akiyama, 2008) and
Sox9’s role in epithelial invasion, migration, and prolifer-
ation in various cancers and its prognostic potential has
been reported (Wang et al., 2008; Chakravarty et al.,
2011a). Moreover, Sox9 deregulation and/or mutation
have been found in several human cancers (Bruun et al.,
2014).
Recently, studies on the immunophenotype of devel-
oping, adult, and neoplastic testicular cells have been per-
formed in dogs to prove their potential role as a relevant
model for human testicular cancer (Banco et al., 2010).
Immunohistochemical expression of
Sox9 protein in immature, mature, and
neoplastic canine Sertoli cells
Introduction
Sox9 is involved in testicular development being a key
testis-determining gene for specifying the Sertoli cell (SC)
lineage (Harley et al., 2003; Sharpe et al., 2003; Bar-
rionuevo et al., 2010). Sox9 transcripts, initially expressed
in the genital ridge of both sexes, becomes upregulated in
SCs, whereas it is downregulated in the ovaries (Morais
da Silva et al., 1996; de Santa Barbara et al., 2000). The
inactivation of Sox9 before the sex determination stage re-
sults in XY sex reversal (Chaboissier et al., 2004; Bar-
rionuevo et al., 2006). Two thirds of XY patients with a
mutation in Sox9 show sex reversal indicating an essential
role of this gene in the testis determination (Foster et al.,
1994). In addition, recent studies reported that Sox9 up-
regulates the production of anti-Muellerian hormone
(Mackay, 2000; Josso et al., 2001), secreted during the em-
bryonic development by SCs and promoting the regression
of the Muellerian ducts ( Josso et al., 1993). This latter
finding supports the crucial role of Sox9 in male sex de-
termination and testicular development. In scientific lit-
erature, few papers investigating the gene expression and
protein localization of Sox9 in normal testis have been
published, and most of them are focused on embryonic
and fetal gonads, both in human and laboratory animals
(Pelliniemi and Frojdman, 2001; Carmona et al., 2009). In
human undifferentiated gonads, Sox9 protein was initially
demonstrated by immunofluorescence in the cytoplasm of
somatic cells and then become restricted to the nuclei of
SCs when sex cord formation begins (de Santa Barbara et
al., 2000) and during all the normal testicular develop-
ment, as demonstrated by immunohistochemistry and in
situ hybridization as well (Hanley et al., 2000).
Besides studies about the embryologic and fetal devel-
opment of the testis, few studies explore Sox9 protein ex-
pression in adult and/or in pathologic testes (Lan et al.,
2013). In mice, the immunohistochemical pattern of Sox9
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Because spontaneous testicular cancers are quite common
in dogs and Sox9 protein expression in normal and neo-
plastic SCs has never been examined in this species, the
present study aimed to investigate the expression of Sox9
protein in canine SCs during testicular maturation and
neoplastic transformation.
Materials and methods
Samples
No animals were killed for this study, and all selected sam-
ples were originally submitted for diagnostic purposes to
departmental routine biopsy or necropsy service. For this
retrospective study, paraffin blocks of formalin-fixed nor-
mal pairs of testes from three canine fetuses (50 days of
gestation), four newborn dogs (from 0 to 20 days of age),
and four prepubertal puppies (56, 90, 120, and 180 days of
age) and from five adult/aged dogs (2, 4, 6, 10 and 13 year
old) were selected from departmental archives. During
sample selection, particular attention was posed to consider
well-preserved testes: not macerated fetal testes, adult nor-
mal testes from routine spaying, immature testes from
well-conserved puppies, submitted for necropsy after sud-
den traumatic death. Regarding neoplastic testes, from the
same diagnostic archive, 31 SC tumors and five Leydig cell
tumors (LCTs) were selected. Sertoli cell tumors (SCTs)
were from dogs ranging in age from 4 to 15 years. One of
these tumors was malignant, with metastases to the lum-
boaortic lymph nodes 2 years after surgical castration; 10
of 31 SCTs developed within cryptorchid testes. LCTs
were from dogs ranging in age 9 to 13 years and all devel-
oped in eutopic testes.
Histology
For each sample, 5-μm-thick sections were obtained and
stained with hematoxylin and eosin. As in previous studies,
the histologic variants of canine SCTs were recorded as
“typical” and “lipid rich” (Banco et al., 2010). The growth
pattern of the SCTs was also recorded and defined as“in-
tratubular” or “diffuse.” Tumors showing both intratubular
and diffuse neoplastic growth were defined as “intratubu-
lar/diffuse.”
The histologic variants of LCTs were classified as
“solid-diffuse” and “cystic-vascular” as reported in the
“World Health Organization International Histological
Classification of Tumors of Domestic Animals” (Kennedy
et al., 1998). For all the neoplastic testes, the mitotic index
(MI) was assessed by counting the mitotic figures in 10
high-power fields (400 x), and the mean value for each
sample was then recorded.
Immunohistochemistry
The immunohistochemical staining of all samples was per-
formed using the avidin–biotin–peroxidase complex pro-
cedure (Hsu et al., 1981) with a commercial
immunoperoxidase kit (Vectastain Standard Elite; Vector
Laboratories, Inc., Burlingame, CA, USA). Sections were
dewaxed, treated with hydrogen peroxide 0.5% in
methanol for 20 min, and rehydrated. Antigen retrieval
was carried out by microwave in citrate buffer, pH 6.0 (10
min, 650 W). After pretreatment, the sections were incu-
bated for 30 min in normal goat serum (diluted 1:60). As
a primary antibody, a rabbit anti-human polyclonal anti-
body directed against Sox9 (Sigma–Aldrich Corporation,
St. Louis, Missouri, USA) was applied and diluted 1:150
in Tris buffer. According to the manufacturer’s instructions,
the antibody was raised against a human Sox9 synthetic
peptide sharing 96% amino acid homology with Canis fa-
miliaris Sox9. Sections were incubated overnight in a
humid chamber at 4°C.
After incubation with the secondary biotinylated anti-
rabbit immunoglobulin (diluted 1:200; Vector Laborato-
ries, Inc.) for 30 min, the avidin–biotin–peroxidase
complex method (Vector Laboratories, Inc.) was per-
formed. The peroxidase reaction was developed by 3-amino
9-ethyl carbazole (Vector Laboratories, Inc.), and sections
were counterstained with Mayer’s hematoxylin. Negative
controls were obtained replacing the primary antibody
with normal goat serum.
Assessment of the immunohistochemical labeling
The percentage of positive cells was semiquantitatively as-
sessed and scored as follows: - = 0; + = 20% or less; ++ =
21% to 50%; +++ = 51% to 80%; ++++ = 81% to 100%.
Results
Histology
Both in fetuses and newborns, the seminiferous tubules
were small, with no recognizable lumen, and lined by un-
differentiated SCs and rare early germ cells.
In the testes from prepubertal dogs, spermatogonia
were recognizable in all samples together with few sper-
matocytes in the oldest one (180 day old). In this latter
dog, a small central lumen was also evident. In the testes
from adult dogs, complete seminal line, including sperma-
tozoa, was evident into the seminiferous tubules.
Regarding SCTs, on the basis of their pattern of
growth, 17 of 31 tumors were classified as “intratubular”
and nine of 31 as “intratubular/diffuse.” Five cases were
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Figure 1. Sox9 protein immunohistochemical expression in non-neoplastic Sertoli cells. (A) Canine fetal testis (Sox9 immunola-
beling). Strong nuclear staining detectable in all Sertoli cells lining the seminiferous tubules. Negative rete testis epithelial cells
are evident at the center of the image. Magnification 100. Scale bar = 70 μm. (B) Canine neonatal testis (Sox9 immunolabeling).
Strong nuclear staining detectable in all Sertoli cells. Magnification 200. Scale bar = 35 μm. (C) Canine prepubertal testis (Sox9
immunolabeling). Sertoli cells in seminiferous tubules from 90-day-old puppy were characterized by both nuclear and cytoplasmic
staining. Magnification 100. Scale bar = 70 μm. (D) Canine adult testis (Sox9 immunolabeling). Strong nuclear staining detectable
in all mature Sertoli cells. Magnification 100. Scale bar = 70 μm. (E) Canine adult testis. Atrophic testicular parenchyma (Sox9
immunolabeling). Atrophic tubules, generally at the periphery of the Sertoli cell tumors, were lined by Sertoli cells characterized
by a strong nuclear labeling. Magnification 100. Scale bar = 70 μm.
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characterized by a “diffuse” pattern of growth; 18 of the
31 tumors examined (12 intratubular, three
“intratubular/diffuse,” and three “diffuse,” respectively)
were classified as typical SCT. These tumors comprised
neoplastic tubules, irregular in shape and diameter, and
surrounded by thick basal membranes. Neoplastic tubules
were separated by a variable amount of dense fibrous
stroma and lined by one to two layers of tall and slender
cells, oriented perpendicularly to the basal membrane in a
palisading arrangement. Neoplastic cells were character-
ized by indistinct cell borders, oval to spindle basal nuclei
with stippled chromatin, and scant to moderate, faintly
eosinophilic cytoplasm.
In 13 of 31 SCTs (five intratubular, six “intratubular/
diffuse,” and two “diffuse”, respectively), neoplastic SCs
contained large intracytoplasmic, round, smooth con-
toured vacuoles displacing the nucleus at the periphery,
giving the cell a signetring appearance. These cases, ac-
cording with a previous report in the canine species
(Banco et al., 2010), were classified as “lipid-rich” SCTs.
Three cases out 31 SCTs, two intratubular typical, and
Fig. 2. Sox9 protein immunohistochemical expression in neoplastic Sertoli cells. (A) Canine intratubular typical Sertoli cell tumor
(Sox9 immunolabeling). Strong nuclear staining in neoplastic SCs. Magnification 50. Scale bar = 130 μm. (B) Canine intratubular
typical Sertoli cell tumor (Sox9 immunolabeling). Strong nuclear and cytoplasmic staining in neoplastic SCs. Magnification 200.
Scale bar = 35 μm. (C) Canine intratubular/diffuse Sertoli cell tumor (Sox9 immunolabeling). Neoplastic tubules filled with Sertoli
cells showing a strong membrane immunostaining. Magnification 400. Scale bar = 20 μm. (D) Canine intratubular, lipid-rich
Sertoli cell tumor (Sox9 immunolabeling). Heterogeneous pattern of expression of Sox9. Neoplastic tubules at the periphery of
the image are lined by neoplastic Sertoli cells characterized by diffuse nuclear labeling, whereas the centrally located tubule is char-
acterized by lesser number of positive Sertoli cells. Strongly immunostained cells are closely opposed to weakly positive or com-
pletely negative ones. Magnification 200. Scale bar = 35 μm.
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one intratubular lipid rich were additionally characterized
by rare Call–Exner bodies, represented by neoplastic SCs
arranged in rosettes surrounding microcavities filled with
hyaline eosinophilic amorphous material.
In nine of 31 SCTs (four typical and five lipid rich),
scattered areas of intratubular necrosis, cystic cavities, and
hemorrhages were present. In three of these nine cases,
neoplastic SCs were characterized by severe anisokaryosis
and anisocytosis, infiltration of the albuginea, and large
areas of necrosis. One case was associated with lumboaor-
tic lymph node metastasis and, thus, was malignant.
In most SCTs (24 of 31), MI was low, ranging from 0
to 0.5. The remaining seven cases had high MI (0.7–2.4). 
Concerning LCTs, three cases, composed by sheets and
cords of polygonal cells separated by scant amount of fi-
brovascular stroma, were classified as “solid-diffuse” LCTs.
One case, characterized by interconnecting cords of neo-
plastic Leydig cells (LCs), surrounding and delineating
large lacunae filled with erythrocytes, was classified as “cys-
tic vascular” LCT. Finally, in one case, both growth pat-
terns were present and it was, therefore, classified as
“solid-diffuse”/“cystic vascular” LCT. Neoplastic cells were
polyhedral to cuboidal, with low N/C ratio, finely granular
eosinophilic cytoplasm, variably distinct cell borders, small
and round eccentric nucleus, and an indistinct nucleolus.
In two cases, large clusters of cells had numerous vacuoles
within the cytoplasm, compressing the nucleus to the pe-
riphery (signet ring cells). In three cases, focal hemor-
rhages were observed. In all the LCTs, MI was less than
one.
Immunohistochemistry
In fetal and neonatal testes, a strong positive and exclu-
sively nuclear immunolabeling for Sox9 protein was de-
tected in all SCs (++++) (Fig. 1A; 1B).
In the testes of the four prepubertal puppies, the im-
munohistochemical staining was variable. In the youngest
and oldest dogs, belonging to this category 56 and 180
days old, intense nuclear expression of Sox9 was detected
in an high percentage of SCs (+++ and ++++, respectively),
similarly to fetal, neonatal, and adult testes. Conversely, the
SCs of the 90-day-old puppy exhibited both strictly nu-
clear or nuclear and cytoplasmic expression of Sox9 (Fig.
1C). In this case, independently from the localization of
the immunohistochemical signal, the percentage of labeled
SCs was assessed as +++. In the 120-day-old puppy, all SCs
were negative.
In adult testes, all SCs exhibited a strong nuclear im-
munolabeling (++++) for Sox9 (Fig. 1D). In all testes ex-
amined, LCs and germ cells were constantly negative for
Sox9.
Regarding the testicular tumors examined, LCTs were
always negative for Sox9 protein, whereas in 31 of 31 SC
tumors, Sox9 was constantly expressed. In 28 of 31, the
percentage of stained SCs was high, ranging from
+++/++++. In only three cases, the percentage of positive
cells was low, less than 50% (++). The signal varied from
nuclear (Fig. 2A), nuclear and cytoplasmic (Fig. 2B), and
exclusively cytoplasmic in 18 of 31, 11 of 31, and two of
31 SCTs, respectively.
Nuclear labeling was observed in 12 typical and six
lipid-rich SCTs; nuclear and cytoplasmic labeling was ev-
ident in six typical and in five lipid-rich SCTs, whereas a
strictly cytoplasmic signal was recorded in two lipid-rich
SCTs. Interestingly, in one lipid-rich SCT, exhibiting both
nuclear and cytoplasmic signal, a strong positive staining
of the membrane of neoplastic cells was observed (Fig.
2C).
Although all the SCTs were positively labeled for Sox9,
they were characterized by an heterogeneous pattern of ex-
pression, particularly evident in the lipid-rich cases: within
a single tubule, most cells could be immunolabeled, or the
positive immunostaining could be restricted to a small
number of cells. Moreover, strongly immunostained
tubules could be adjacent to weakly positive or completely
negative ones (Fig. 2D).
Within the atrophic testicular parenchyma surrounding
both SCTs and LCTs, Sox9 immunolabeling was con-
firmed to be strictly limited to SC nuclei (Fig. 1E).
Sox9 immunohistochemical results are summarized in
tables 1 and 2.
Discussion
In mammals, numerous studies focusing on the genetic
regulation of mammalian gonads reported the pivotal role
of Sox9 gene in male gonadal development. Highly con-
served among vertebrates, Sox9 gene expression was al-
ready demonstrated by polymerase chain reaction in testes
of canine fetuses from 27 to 37 days of gestation (Meyers-
Wallen, 2003).
On the other hand, scarce information about immuno-
histochemical Sox9 protein expression and localization in
postnatal testes is present in literature, and data about its
expression in testicular tumors are lacking. The present
study investigated the immunohistochemical expression of
Sox9 in normal canine testes, from fetal to adult age, and
in tumors derived from SCs and LCs.
In the dog, Sox9 immunolabeling was confirmed to be
limited to the nucleus of SCs in fetal, neonatal, and normal
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adult testes, as already described in human species and lab-
oratory animals (Morais da Silva et al., 1996; de Santa
Barbara et al., 2000; Frojdman et al., 2000; Hanley et al.,
2000; Nel-Themaat et al., 2011; Lan et al., 2013). Inter-
estingly, in the testes from the four prepubertal dogs, the
immunohistochemical expression of Sox9 protein was
highly variable. In the youngest and oldest dogs (56 and
180 days old), Sox9 was restricted to the nucleus of SCs,
as observed in fetal and neonatal testes, whereas in the
120-day-old pup no expression of Sox9 was observed. In
the 90-day-old dog, Sox9 expression reappeared and was
detectable both in the nucleus and in the cytoplasm. Sim-
ilar variations in Sox9 protein expression have been re-
ported in rat gonads. In rats, nuclear Sox9 expression was
described in SCs of fetal testes and then the immunore-
action gradually declined, becoming faintly positive to
negative in postnatal rats. From the onset of puberty until
15-day-old rats, Sox9 protein expression returned and in-
creased (Frojdman et al., 2000; Pelliniemi et al., 2001).
These authors suggested that the presence and amount of
Sox9 protein could be dependent on the age and the sper-
matogenetic stage within the seminiferous tubules. Al-
though the present study only examined four prepubertal
dogs and, in particular only one of 120 days, the results
seem to parallel what is observed in rats, suggesting a sim-
ilar biologic role. However, these results deserve to be ver-
ified on a larger number of samples.
In all testes examined, seminal and LCs were always
negative, consistently with results obtained in other mam-
mals (de Santa Barbara et al., 2000; Lan et al., 2013). In
addition, Sox9 immunohistochemical signal was absent in
all LCTs, whereas SCTs were constantly positive. These
results confirmed that in canine testis Sox9 protein could
be considered a reliable marker for normal and neoplastic
SC and could be used to discriminate between LCTs and
SCTs, in particular the lipid-rich variant. In fact, LCTs
and SCTs share morphologic features although having dif-
ferent clinical outcomes: LCT is a benign tumor, whereas
malignant and metastasizing SCTs have been described
(MacLachlan and Kennedy, 2002).
In the present study, all the SCTs were positively la-
beled. A strong immunohistochemical signal, varying from
51% to 100% of neoplastic cells was observed, confirming
that Sox9 protein remains a specific marker of SCs, also
in the neoplastic counterpart. In most SCTs (18 of 31),
Sox9 labeling was exclusively nuclear, as observed in nor-
mal testes, whereas in 11 of 31 cases the signal was nuclear
and cytoplasmic and in two of 31 exclusively cytoplasmic.
The cytoplasmic expression of Sox9 protein observed
both in neoplastic samples and in one prepubertal pair of
testes is an interesting finding that deserves some consid-
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No. Breed Age
SOX9 immunolabeling
% labeled cells Signal localization
1 Mixed breed Fetus (50d gestation) ++++ N
2 Mixed breed Fetus (50d gestation) ++++ N
3 Mixed breed Fetus (50d gestation) ++++ N
4 West Highland White terrier Stillborn ++++ N
5 Boxer Stillborn ++++ N
6 Mexican hairless dog 3d ++++ N
7 Mexican hairless dog 20d ++++ N
8 Rough collie 56d +++ N
9 Mixed breed 90d +++ N/C
10 English bulldog 120d - N
11 American staffordshire 180d ++++ -
12 Golden retriver 2y ++++ N
13 German shepard 4y ++++ N
14 Mixed breed 6y ++++ N
15 Dachshund 10y ++++ N
16 Mixed breed 13y ++++ N
- = 0; +++ = 51%–80%; ++++ = 81%–100%.
Abbreviations: C, cytoplasmic; N, nuclear; NC, nuclear and cytoplasmic.
Table 1. Expression of Sox9 in fetal, neonatal, prepubertal and adult testes.
31SOX9 in male gonad
No. Breed Age Growth Variant
Necrosis and
hemorrhages
MI
SOX9 immunolabelling
Percentage
of labeled cells
Signal 
localization
1 German Shepherd 4 D T X 2,4 +++ N/C
2 German Shorthaired Pointer 4 D LR X 1,1 ++++ N/C
3 Boxer 5 D T X 1,6 +++ N/C
4 Chihuahua 6 I T 0,1 ++++ N
5 Mixed breed 6 I/D T X 1 ++ N/C
6 Rough Collie 7 I T 0,1 ++++ N
7 Cocker spaniel 7 I LR 0,1 ++++ N
8 Alaskan malamute 7 I T 0,3 ++++ N
9 Mixed breed 7 I T 0,3 ++++ N
10 Mixed breed 8 I LR 0 ++++ N
11 Dalmatian 8 D T 1,2 +++ N/C
12 German Shorthaired Pointer 8 I LR 0,2 ++++ N
13 Mixed breed 9 I T 0 ++++ N
14 Belgian Shepherd 9 I T 0 ++++ N
15 German Shepherd 10 I T 0,1 +++ N
16 Labrador Retriever 10 I/D LR 0,1 +++ C
17 Doberman Pinscher 10 I/D LR X 0,8 +++ N/C
18 Springer Spaniel 10 I T 0,2 +++ N
19 Bergamasco Shepherd 11 I T 0,3 +++ N/C
20 Mixed breed 11 D LR X 0,1 ++++ C
21 German shepherd 12 I/D T 0,3 ++++ N
22 Beagle 13 I T 0,1 ++++ N
23 Mixed breed 14 I LR X 0,3 +++ N/C
24 Yorkshire Terrier 14 I/D LR X 0,2 +++ N/C
25 Mixed breed 15 I/D LR 0,3 ++++ N
26 Mixed breed NR I T 0,2 +++ N/C
27 Shetland Sheepdog 7 I LR 0,5 +++ N
28 Boxer 5 I/D LR 0,4 ++ N
29 German Shepherd 4 I/D T 0,4 +++ N
30 Airedale Terrier 5 I/D LR 0,5 ++ N/C Membrane
31 German Shepherd NR I T X 0,7 ++++ N
32 Beagle 9 SD 0 - -
33 American Staffordshire Terrier 10 CV L X 0 - -
34 Dalmatian 11 SD 0 - -
35 Mixed breed 12 SD/CV L X 0 - -
36 Yorkshire Terrier 13 SD X 0 - -
- = 0; ++ = 21%–50%; +++ = 51%–80%; ++++ = 81%–100%.
Abbreviations: C, cytoplasmic; CV, cystic vascular; D, diffuse; I, intratubular; I/D, intratubular/diffuse; LR, lipid rich; MI, mitotic
index; N, nuclear; NR, not reported; SD, solid diffuse; SD/CV, solid-diffuse/cystic vascular; T, Typical.
Table 2. Expression of SOX9 in neoplastic testes.
eration. Cytoplasmic Sox9 protein expression has been de-
scribed in the early stage of testicular development. In both
murine and human species, during early gestation, Sox9
gene is upregulated in the male. Simultaneously, Sox9 pro-
tein, which appears cytoplasmic in the undifferentiated go-
nads, becomes nuclear in pre-SCs (Morais da Silva et al.,
1996; de Santa Barbara et al., 2000). On the basis of these
observations, we hypothesize that the cytoplasmic expres-
sion of Sox9 protein in prepubertal and neoplastic SCs
could be related to functional immaturity or alternatively
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could represent an undifferentiated, not fully developed
SC transient phenotype, similarly to what observed during
the testicular development. The dynamic subcellular redis-
tribution of Sox9 protein in the gonads at the time of sex-
ual differentiation has been described both in humans and
mice (Morais da Silva et al., 1996; De santa Barbara et al.,
2000) demonstrating that Sox9 is able to shuttle between
the nucleus and the cytoplasm, hypothesizing the exis-
tence of a nuclear export signal triggering male-specific
sexual differentiation (Gasca et al., 2002). In human med-
icine, no data regarding testicular neoplasm and Sox9 pro-
tein expression are present, but this marker has been used
on other neoplastic tissues (mammary gland and ovaries)
revealing interesting results in a subset of cases, such as
cytoplasmic and/or membranous labeling (Zhao et al.,
2007; Bratthauer and Vinh, 2009; Bruun et al., 2014).
Sox9 is a transcription factor; thus, the nuclear distri-
bution of this protein is an expected finding, compared
with cytoplasmic and membranous staining. According to
Chakravarty et al. (2011a), cytoplasmic Sox9 in breast can-
cer is associated with invasive and metastatic breast carci-
nomas and it is related to increased cell proliferation.
Similarly, in two thirds of ductal breast lesions, Sox9 pro-
tein was located in the cytoplasm and not in the nucleus
(Bratthauer and Vinh, 2009). Moreover, cytoplasmic and
membranous Sox9 staining has been found in “borderline”
ovarian tumors and not in well differentiated ones (Zhao
et al., 2007). Therefore, the results of our study could sup-
port the hypothesis that the cytoplasmic expression of
Sox9 in neoplastic SCs reflects a less differentiated phe-
notype. This point could be relevant and should be ex-
plored in future studies.
Moreover, although all SCTs were Sox9 positive, a
variable number of negative neoplastic cells were evident
in all the SCTs examined. In addition, in this study, one
prepubertal pair of testes was characterized by the lack of
Sox9 expression, similarly to a minority of neoplastic SCs
not labeled in the SCTs. Regarding normal canine prepu-
bertal SCs, we hypothesize that the negative Sox9 labeling
parallels the results observed in rat gonads (Frojdman et
al., 2000), suggesting that Sox9 expression, before adult-
hood, is unstable and physiologically reduced. In the same
way, negative neoplastic SCs could reflect a more imma-
ture or dedifferentiated immunophenotype.
The results obtained from this first study investigating
Sox9 protein expression in normal and neoplastic canine
testes suggest that this protein may play a role in SC pro-
liferation and neoplastic transformation. However, further
investigations on a larger number of samples are required
to confirm these hypotheses.
On the other hand, the consistent expression of Sox9
in the SCTs, together with the consistent negative results
obtained in LCTs, show that Sox9 is a reliable marker for
confirmatory diagnosis of these tumors in dogs.
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ceptor, progesterone receptor and HER2/Neu negative
breast cancer), Slug, Sox9 and Sox10 were overexpressed
in the nuclea or in the cytoplasm of neoplastic cells and
associated with poor overall survival (Riemenschnitter et
al., 2013).
High Sox9 expression in basal-like breast cancer cor-
relates with poor prognosis and activation of Wnt/β-
catenin pathway; Sox9 silencing reduced cell proliferation
and invasion (Malhotra et al., 2014). Wnt family is com-
posed by a number of highly-conserved proteins involved
in many developmental processes such as cell embryonal
differentiation and migration, cell proliferation and regen-
eration in adult tissues, governing somatic stem cells func-
tion (Davis and zur Nieden, 2008). Moreover it has
emerged that genes encoding for Wnt pathway compo-
nents are often altered in human cancer and disease (Davis
SOX9 in mammary gland neoplasms
In recent years identification and characterization of mo-
lecular controls that regulate mammary stem and progen-
itor cell homeostasis are critical to our understanding of
normal mammary gland development and its pathology,
neoplastic lesions included. Up to now there are few stud-
ies concerning this issue, and a consistent of them are
about Sox9 role in human brest carcinoma.
Recent evidence suggests that human breast cancer
stem cells are controlled by key regulators similar to those
operating in normal mammary stem cells (Guo et al.,
2012). Stem cells can be classified in two main groups: em-
bryonic stem cells, with an unlimited self-renewing capac-
ity, and adult stem cells or somatic stem cells, with a
restricted lineage potential. Somatic stem cells are present
in almost every tissue of the body and are capable of multi-
lineage or uni-lineage differentiation only, as they are re-
sponsible for physiologic tissue turnover (Davis and zur
Nieden, 2008).
Afonja et al. (2002) first, found Sox9 expression in
breast cancer cell lines. In mammary neoplastic tissue, in-
stead, Sox9 expression was found in 4 cases of matrix-pro-
ducing carcinoma of the breast, an extremely rare and
specialized variant of metaplastic carcinoma of the breast.
Immunopositivity for Sox9 was more diffuse in the nuclei
of metaplastic cancer cells than in carcinomatous cells.
Sox9 protein in matrix-producing carcinoma of the breast
was moreover associated with differentiation of neoplastic
epithelial cells to chondrocytic cells (Kusafuka et al., 2008).
Another study showed a correlation between Sox9 and
breast tumor cell proliferation, demonstrating the prog-
nostic significance of this marker in case of invasive ductal
carcinomas and metastatic breast cancer. Patients with
higher Sox9 expression indeed had significantly shorter
overall survival. Sox9 expression in neoplastic cells was de-
tected in the cytoplasm, instead of nucleus; this cytoplas-
mic accumulation, observed in about 30% of invasive
ductal carcinomas and lymph node metastases, was signifi-
cantly correlated with enhanced proliferation in breast tu-
mors (Chakravarty et al., 2011a, 2011b); Sox9 cytoplasmic
sequestration seems to be implicated in tumor progression
(Chakravarty et al., 2011b). In case of invasive breast can-
cer, especially in triple negative phenotype (estrogen re-
Figure 1 (from Guo et al., 2012). Sox9 and Slug effects on differ-
ent mammary epithelial lineages. Red dashed lines indicate the
morph of a differentiated cells into stem (MaSCs) or progenitor
cells through the induction of the transcriptor factor indicated.
Sox9 together with Slug was sufficient in reprograming mature
luminal mammary epithelial cells into MaSCs while Sox9 ex-
pression by itself converted these cells into luminal progenitors
(Malhotra et al., 2014). It is not clear whether Sox9 by itself
changes myoepithelial progenitors or myoepithelial differenti-
ated cells into MaSCs and/or expands a preexisting MaSCs
population (Guo et al., 2012).
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and zur Nieden, 2008). Sox9 overexpression in cell lines
increased Wnt signaling transgenic overexpression and, in
vivo in murine mammary glands increased secondary duc-
tal branching (Malhotra et al., 2014). Sox9 acts in coop-
eration with Wnt in various stem cell systems (Blache et
al., 2004), and it seems that Wnt/β-Catenin pathway plays
a key role in MaSCs maintenance too. Thus, Sox9 is an
important component of MaSCs maintenance by Wnt/β-
Catenin and potentially other pathways (Malhotra et al.,
2014).
With concern to other transcription factors families,
forced expression of Slug and Sox9 in breast cancer cells
was demonstrated to promote the tumorigenesis and
metastasis; it induce, indeed, the entrance of cells in a TIC
(tumor-initiating cells) state, that is responsible for
metastatic dissemination and clinical relapse in several
cancers, with subsequent poor patient outcomes (Guo et
al., 2012; Ye et al., 2015; Fazilaty et al., 2015). Guo et al.
(2012) investigated the correlation between EMT and sta-
minal property acquisition from normal differentiated
mammary cells and neoplastic cells through the expression
of the transcription factors Sox9 and Slug. In healthy
mammary gland, Sox9 and Slug function as master regu-
lators of the gland-reconstituting activity of normal mam-
mary stem cell; they cooperate inducing differentiated
luminal cells of the mammary gland into mammary stem
cells. Differentiated mammary luminal cells expressing
both Sox9 and Slug were able to activate an endogenous
autoregulatory network in somatic stem cells and recon-
stitute an entire mammary gland (Guo et al., 2012) (Fig.
1). In the same study coexpression of Slug and Sox9 was
demonstrated to promote the tumorigenesis and metasta-
sis of human breast cancer cells and are associated with
poor patient outcomes (Guo et al., 2012).
Figure 2 (from Ye et al., 2015). Snail activation is associated with invasiveness in mammary tumor cells. Expression patterns of
Snail and Slug in normal mammary epithelium and in different stages of mammary tumor development. Markers CK8 and CK14
are expressed respectively in luminal mammary epithelial cells (MECs) and in basal cells MECs. As tumor progresses, cells acquire
basal CK14 expression and lose luminal CK8 expression (Ye et al., 2015).
The last study on this issue (Ye et al., 2015) gained new
insights in mammary gland neoplasms development and
in Guo et al. (2012) findings. Researchers found that Snail,
member with Slug of the EMT-inducing family of tran-
scription factors, was absent in normal mammary epithe-
lial cells but become activated during breast cancer
progression (Fig. 2). Slug and Snail induce distinct EMT
programs; both Slug and Snail, in collaboration with Sox9,
can efficiently induce a TIC phenotype in breast cancer
cells, but Snail subpopulation showed more than two or-
ders of magnitude higher proportions of TICs than the
other subpopulations. Moreover Snail cells were more able
to seed pulmonary metastases than Slug population. In a
panel of human breast cancer cell lines, Snail knockdown
suppressed tumor initiation in most of them, while Slug
knockdown failed to do so (Ye et al. 2015). On the other
hand, Slug knockdown significantly affected normal
MaSCs in their gland reconstituting activity. It was more-
over demonstrated that Snail TICs did not arise from
basal MaSCs-like (expressing high Slug levels), but they
came from a different population of cells. According to
data obtained, the authors suggest that normal stem cells
and TICs could arise from different cellular compartments
and activate different signaling pathways. Moreover the
high Slug expression previously associated to poor prog-
nosis in breast cancer patients, may be thus related to Slug
MaSCs basal differentiation, that on its own, represents a
well-known feature of aggressive cancers (Ye et al., 2015).
This last investigation has thrown up many new ques-
tions regarding Snail, Slug and Sox9 role in cancer devel-
opment. More research is needed to better understand the
mechanisms of stem cells regeneration and maintenance
in order to find maybe new strategies for treating degen-
erative diseases and cancer ( Jo et al., 2014).
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Sox9 expression in feline mammary hy-
pertrophy
Introduction
Feline mammary hypertrophy (FMH) is a progesterone-
responsive non-neoplastic proliferation of the mammary
gland of the cat characterized by sudden and rapid onset
(Hayden et al., 1981). This pathological condition has been
also described with the name of fibroadenomatous change
or benign mammary hypertrophy (Nimmo and Plummer,
1981). At about 20% of benign lesions of the cat mam-
mary gland is represented by FMH lesions (Gorlinger et
al., 2002). FMH occurs mainly in young females, during
pregnancy or false pregnancy and due to progestin treat-
ments. In older males this condition is always related to
the last one (Hayden et al., 1989; Loretti et al., 2004; Son-
tas et al., 2008). Physical features of FMH are primarily
characterized by a rapid enlargement of one or all mam-
mary glands without milk production (Gorlinger et al.,
2002). Histologically FMH can be classified in intraductal
and solid fibroepithelial type. Intraductal fibroepithelial
hyperplasia was further subdivided into papillary and cir-
cumferential types, where neoplastic proliferation occurs
into the lumen of a very dilated duct. Solid form, instead,
shows a compact and ring-shaped pattern that infiltrates
stromal cells (Hayden et al., 1989). FMH treatments in-
clude progestin administration interruption, ovariectomy,
mastectomy in case of failure of the previous choices, or
anti-progestins administration (Leidinger et al., 2011).
Since 1973 (Allen et al., 1973) an hormonal cause was
suspected and subsequent studies confirmed a correlation
between progesterone treatment and FMH occurrence
(Hayden et al., 1989; Loretti et al., 2004), but mechanisms
that drive these changes are still debated. Progesterone re-
ceptors have been detected in both epithelial and stromal
cells of FMH cases (Rutteman et al., 1991; Martin de las
Mulas et al., 2000; Gracanin et al., 2012) while estrogen
receptors were present only in 50% of cases (Martin de las
Mulas et al., 2000). Progesterone is an important regulator
for mammary stem and progenitor cells: this hormone
leads staminal cells close to the progesterone expressing
cells to proliferate and differentiate (Gracanin et al., 2012).
Moreover, through a cascade of signals progesterone-in-
duced involving growth hormone (GH) and subsequently
insulin-like growth factor (IGF), epithelial and stromal
cells proliferate. The progesterone-induced GH production
in the mammary gland leads to local production of IGF,
so this growth-promoting effect is modulated by autocrine
and/or paracrine mechanisms. This local stimulation may
be the reason why FMH in a number of cases progresses
even after ovariectomy and progesterone absence (Gor-
linger et al., 2002; Ordás et al. 2004; Zegers, 2011).
High Ki-67 proliferative index has been reported in
FMH in several studies (Millanta et al., 2002). However,
many pathogenic aspects have not been clearly elucidated
yet. Recent studies indicated that SOX9 transcription fac-
tor, in cooperation with Slug, controls the mammary stem
cell state (Guo et al., 2012) and that increased ductal
branching may be observed in transgenic mice overex-
pressing SOX9 in mammary epithelium (Wang et al.,
2013).
Aim of the study
The aim of this study is to gain insight into the role of
SOX9 in FMH development, analyzing by immunohisto-
chemistry SOX9 expression in FMH, non-FMH hyper-
plastic/dysplastic mammary lesions and normal mammary
tissue of cat.
Materials and methods
Formalin fixed paraffin embedded tissue blocks of surgical
biopsy were retrieved from archives as follows: samples of
10 FMH, 6 non-FMH hyperplastic/dysplastic mammary
lesions and 3 normal mammary gland of female cats.
The diagnosis of each tumor was revised according to
the criteria of the World Health Organization classifica-
tion.
Signalment and anamnestic data of the patients were
collected.
Tissue samples were examined for SOX9 expression by
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Figure 1. Sox9 immunohistochemistry on feline mammary
gland, haematohylin counterstain. (A) Normal mammary gland
with moderate Sox9 response (obj. 40 x). FMH lesions with
strong positivities in ducts (B) (obj. 20 x) and moderate im-
munostaing in stromal cells (C) (obj. 20 x). (D), (E) Hyperplas-
tic/dysplastic lesions with strong immunolabeling (obj.40 x).
ABC immunostaining method, using a polyclonal rabbit
serum produced with a polypeptide with 97% identity
with Felis catus Sox9 (Sigma-Aldrich, Prestige antibodies,
HPA001758).
Serial sections (4 μm) on poli-L-lysine coated glass
were dewaxed, treated with hydrogen peroxide 0.5% in
methanol for 20 min, and rehydrated. Antigen retrieval
was carried out by microwave in 0,01 M citrate buffer, pH
6.0 (10 min, 650 W). Slides then were rinsed in TRIS and
incubated in normal serum goat for 30 min at room tem-
perature. The sections then were incubated with primary
anti-Sox9 antibody diluted 1:200 and incubated at 4°C
overnight.
After incubation with the secondary biotinylated anti-
rabbit diluted 1:200 (Vector Laboratories, Inc.) for 30
min, the avidin–biotin–peroxidase complex method (Vec-
tor Laboratories, Inc.) was performed. The peroxidase re-
action was developed by 3,3-diaminobenzidine (DAB)
(Vector Laboratories, Inc.), and sections were counter-
stained with Mayer’s hematoxylin. Negative controls were
obtained replacing the primary antibody with normal goat
serum.
Evaluation of immunohistochemical staining
Immunohistochemical stained tissue slides were exam-
ined using standard light microscopy. Immunolabeling of
epithelial cells and myoepithelial cells of mammary gland
(ducts) were counted separately from stromal myofibrob-
lasts. Cutaneous adnexa in healthy skin, when present,
were employed as internal positive control.
Intensity was scored as negative=0; weak=1; moder-
ate=2; intense=3. Percentage of reacting cells was evaluated
by counting 1000 cells. Immunostaining was localized and
assessed as nuclear or cytoplasmic, or both.
Results
The 3 control-cats of the study, with normal mammary
gland, were aged 7-12 years (average 9,7); the average age
of 10 FMH cases was 4,9 years (animals aged 4 months-
14 years); 6 subjects with other dysplastic lesions were aged
6 – 13 years (average 10 years).
In one case, normal mammary gland tissue came from
castrated cat. Dysplastic lesions were all from sterilized an-
imals, whilst FMH samples were from female cats (8
cases), castrated (1 case) and unknown (1 case).
Positive Sox9 immunostaining of variable intensity and
percentage was seen in all the samples analyzed and was
essentially nuclear or in a few cases nuclear and weakly cy-
toplasmic. In normal mammary gland (Table I) Sox9 was
detected both in epithelial and in myoepithelial cells. Per-
centage of positive cells ranged from 33.2% to 55.4%
(mean value 40.5%) (Fig. 1A). Sox9 positive staining was
seen only in a few stromal cells. Intensity was strong in
one case and moderate and in 2 cases.
All FMH samples showed moderate to strong Sox9 ex-
pression both in glandular and in stromal tissue (Table II);
positivity ranged from 81.6% and 94.5% (mean value
86.5%) in ductal cells (Fig. 1B) and from 51.4% and 86%
(mean value 75.1%) in stromal fibrocytes (Fig. 1C).
In non-FMH hyperplastic/dysplastic lesions staining
was intense and percentage of positive cells varied from
60.3% to 71.9% (mean value 66.4%) (Fig. 1D; 1E); Sox9
positive staining was infrequent in stromal fibrocytes
(Table III).
Discussion
Up to now a number of studies reported that FMH occurs
mainly in young female cats (Hayden et al., 1989; Gor-
linger et al., 2002; Loretti et al., 2004; Sontas et al., 2008);
our results confirm this previously described trend, with
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Tabella I. Sox9 immunohistochemical results in normal mammary glands.
Normal mammary
gland case
Intensity Localization Score Percentage Notes
1 Intense Nuclear 3 54,9% --
2 Moderate Nuclear 2 33,2% Intense hair folliclepositivity
3 Moderate Nuclear 2 33,3% Moderate hair folli-cle positivity
Table II. FMH Sox9 immunohistochemical results.
FMH case Intensity Localization Score Percentage
1 Intense Nuclear 3 Ducts: 93,1%Stroma:76,0%
2 Intense Nuclear 3 Ducts: 86,6%Stroma: 60,0%
3 Intense Nuclear 3 Ducts: 87,0%Stroma:84,6%
4 Moderate Nuclear/Cytoplasmic 2
Ducts:82,1%
Stroma: 75,9%
5 Intense Nuclear 3 Ducts:82,2%Stroma:85,1%
6 Intense Nuclear 3 Ducts: 94,5%Stroma: 77,2%
7 Intense Nuclear 3 Ducts: 84,0%Stroma: 86,0%
8 Moderate Nuclear/Cytoplasmic 2
Ducts: 87,8%
Stroma: 73,5%
9 Moderate Nuclear 2 Ducts: 81,6%Stroma: 51,4%
10 Intense Nuclear 3 Ducts: 86,3%Stroma: 81,0%
Table III. Other dysplastic lesions Sox9 immunohistochemical results.
Other displastic le-
sions 
Intensity Localization Score Percentage Notes
1 Intense Nuclear 3 60,3% Ductal hyperplasia 
2 Intense Nuclear 3 62,8% Hyperplasia edectatic ducts
3 Intense Nuclear 3 64,6% Multiple ductal cyst
4 Intense Nuclear 3 68,5% Lobular hyperplasia
5 Intense Nuclear 3 70,2% Lobular hyperplasiaand ductal cysts
6 Intense Nuclear 3 71,9% Lobular and ductalhyperplasia
most of FMH cases recorded in non-castrated female cats
with an average age of 4,9 years.
This study provide evidence that in feline mammary
FMH both glandular and stromal cells express high levels
of SOX9. Different levels of this transcription factor have
been found among FMH, other dysplastic lesions and
healthy mammary gland. According to previous reports on
Sox9 expression in normal and neoplastic tissue, Sox9 im-
munolabeling was in most of cases nuclear, and sometimes
both nuclear and cytoplasmic. The significance of this find-
ing is still debated. Considered by some Authors as not
specific, cytoplasmic immunostaining in Chakravarty et al.
(2011a,b) studies is associated to a poor prognosis.
Sox9 role in normal mammary gland and mammary
gland neoplasms needs to be clarified yet but together with
Slug, Sox9 act on mammary epithelial cells and morph
them into stem cells able to regenerate mammary ductal
tree (Guo et al., 2012). Sox9 moreover is expressed in
mammary basal-like o triple-negative carcinomas
(Riemenschnitter et al., 2013; Wang et al., 2013); cyto-
plasmic (Chakravarty et al., 2011a,b) or nuclear (Guo et
al., 2012), its presence is always associated to poor prog-
nosis. FMH is a non-neoplastic benign lesion; the high
positivity rate of ductal cells and stromal cells may be re-
lated to the presence of normal mammary cell turnover.
During developmental processes of mammary gland, as in
case of mammary ductal side-branching morphogenesis
and alveologenesis (Lain et al., 2013), Sox9 is widely pres-
ent in epithelial cells of the branching ductal structures
(Chakravarty et al., 2011b; Guo et al., 2012). The mam-
mary ductal side-branching occurs in puberty (following
hormonal/estrogenic stimuli) and pregnancy (progesterone
induced) (Lain et al., 2013). Mammary ductal tree growth
comes from the interaction among progesterone and its
receptors in mammary epithelial cells. Subsequently, in
FMH pathogenesis, GH and IGF production are induced
(Gorlinger et al., 2002; Zegers, 2011), but there are many
other transcription factors involved and that play impor-
tant roles in ductal epithelial cells proliferation. Up to now
only few of them have been identified. Among them An-
phiregulin (Ciarloni et al., 2007; Booth et al., 2010), Msx2
(Fleming et al., 2012), Wnt4 (Brisken et al., 2000; Robin-
son et al., 2000) and RANKL (Beleut et al., 2010). It is
possible that other Wnt proteins contribute to hormone
response, even if their role has not elucidated yet (Roarty
et al., 2012).
Sox9 is part of Msx2 and Wnt signaling pathway,
where Sox9 regulates the expression of Low Density
Lipoprotein Receptor-related Protein 6 (LRP6) and of T-
cell Factor 4 (TCF4), both representative elements of the
Wnt/β-catenin signaling pathway (Wang et al., 2013). In
general, therefore, it seems that both progesterone and
Sox9 act on undifferentiated mammary epithelial cells in-
ducing encoding of transcription factors involved in mam-
mary gland side-branching. However it is still to clarify if
and how progesterone and/or its receptors can activate
Sox9 transcription determining its overexpression in
FMH.
Various studies suggest now that SOX9 plays multiple
important roles in branching morphogenesis of several or-
gans (Furuyama et al., 2011; Rockich et al., 2013), it can
be hypothesized therefore that also in FMH SOX9 drives
branching morphogenesis by controlling proper balance
between proliferation and differentiation.
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Sox9 expression in feline mammary
carcinomas
Introduction
Mammary gland neoplasms in cat are usually aggressive
carcinomas (Hayden and Nielsen, 1971; Hayes, 1981;
Hayes and Mooney, 1985; Amorim, 2006; Zappulli et al.,
2013), with a ratio among malignant and benign tumors
that accounts for 4.1 (Misdorp et al., 1999) to 9:1 (Hayes
et al., 1981). Feline mammary carcinomas (FMC)consti-
tute approximately 17% of all feline neoplasms (Zappulli
et al., 2015); they show high infiltration and local relapse
rate and frequent metastases (Seixas et al., 2007). They
seed metastases in 22,7% (Hayes et al., 1981) to 70,6%
(Weijer et al., 1972) of cases, especially in regional lymph
nodes and lungs (Weijer et al., 1972; Hayden e Nielsen,
1971). FMC usually occurs in queens, with a risk to de-
velop neoplastic lesions 7 times higher than in castrated
animals (Morris, 2013). In only 1-5% of cases, FMC are
reported in male cats (Skorupski et al., 2005). Adult cats
aged 10-12 years represent the target population for this
lesion, but FMC have been signalled in cats from 9
months to 23 years of age. It seems there is a breed pre-
disposition to FMC development in Siamese cat (Morris,
2013). FMC are induced by hormonal fluctuations asso-
ciated to repeated estrus cycles. Repeated progestins treat-
ments, indeed, increase the risk of developing FMC, even
in males. Oncogenic effect of sexual steroid leads to tumor
initiating. Hormonal fluctuations modify mammary tis-
sues; estrogen and progesterone receptors are found in
normal mammary tissues and in benign tumors but are
often lost in malignant tumors and metastases (Morris,
2013). Mammary tumors appear as a single subcutaneous
mass or nodule within the mammary gland, but multiple
mammary masses involving several glands are common.
Sometimes they are ulcerated in appearance, in few cases
cystic (Morris, 2013).
In accordance with World Health Organization
(WHO) classification of tumors of domestic animals,
FMC are divided in non-infiltrating in situ carcinomas
and in infiltrative simple carcinomas of different histologic
subtypes (Misdorp et al., 1999; Zappulli et al., 2013). Re-
cently Zappulli et al. (2013) proposed a revision of feline
mammary neoplasms, assimilating the WHO classifica-
tion. In contrast to canine mammary neoplasms, feline
ones are less heterogeneous; simple adenocarcinoma, aris-
ing from luminal epithelium of ducts and alveoli, is the
most common form of FMC and shows an aggressive be-
havior (Zappulli et al., 2013, 2015). The typical myoep-
ithelial feature of canine complex tumors is missing
(Zappulli et al., 2013). According to this interpretation,
the term “complex” should be avoided in cats, and Authors
propose to classify feline mammary tumors (FMT) with
a myoepithelial component as ductal adenoma/carcinoma
and intraductal papillary adenoma/carcinoma, respectively
(Zappulli et al., 2013). Survival rate is determined by
means of prognostic parameters that include stage based
on tumor size, lymph node status, and metastases; histo-
logic grade; molecular markers, gross appearance, histo-
logical type, molecular markers, tumor grading and lymph
node/lymphovascular invasion (Webster et al., 2011; Zap-
pulli et al., 2015). Mastectomy represent the most em-
ployed therapeutic approach for malignant tumors;
neoplastic tissue and regional lymph nodes are surgically
removed (Gimenez et al., 2010). Chemotherapy results
gave conflicting results, but generally positive (Lana et al.,
2001; Novosad et al., 2006).
The purpose of this study was to determine the im-
munohistochemical expression of Sox9 transcription fac-
tor in FMC in order to evaluate its possible involvement
in the pathogenesis of this tumor.
Materials and methods
39 cases of FMC were selected from the archive of the
Department of Veterinary Medicine as follows: 22 cases
of tubulopapillary carcinomas, 11 cases of cribriform car-
cinomas, 4 solid carcinomas and 4 complex ductal carci-
nomas. Normal skin tissue surrounding the tumor was also
included in the study. Age and breed of the subjects were
collected. The diagnosis of each tumor was revised accord-
ing to the criteria of the World Health Organization clas-
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sification.
For immunohistochemical examination, 4 μm sections
from routine formalin-fixed, paraffin-embedded samples
were prepared on poly-L-lysine-coated glass slides. Sec-
tions were deparaffinized in xylene and rehydrated through
graded alcohols. Endogenous peroxidase was blocked
using 3% hydrogen peroxide in distilled water for 5 min,
then, antigen retrieval for formalin-fixed samples was ac-
complished by microwave irradiation in 0,01 M citrate
buffer, pH 6.0, for 10 min. Sections were incubated in nor-
mal goat serum for 30 min at room temperature. Later
they were incubated for 18 h at 4°C with anti-Sox9 rabbit
polyclonal antibody (HPA001758; Sigma-Aldrich, St.
Louis, MO, USA) diluted 1:200. The antibody recognizes
a Sox9 specific peptide of 117 amino acids with 97% iden-
tity with Felis catus. The sections were incubated for 30 min
with 1:200 goat anti-rabbit biotin (Vector Laboratories,
Burlingame, CA, USA; BA 1000), and stained for 30 min
with streptavidin-biotin peroxidase kit (Vectastain Elite
ABC, Vector Laboratories, PK-6100). The peroxidase re-
action was developed by 3,3-diaminobenzidine (DAB)
(Vector Laboratories, Inc.), and sections were counter-
stained with Mayer’s hematoxylin. Negative controls were
obtained by omission of the primary antibody.
Evaluation of immunohistochemical staining
The immunohistochemically stained tissue slides were ex-
amined using standard light microscopy. Sox9 expression
was classified into 4 groups according to the proportion of
positive cells: 0 = no positive cells; 1 = <10% positive cells;
2 = 10-50% of positive cells; 3 = >50% of positive cells. In-
tensity was scored as negative = 0; weak =1; moderate = 2;
intense = 3. A total score was conferred multiplying the
positive cells percentage score and the intensity of im-
munolabeling score. Cutaneous adnexa in healthy skin,
when present, were employed as internal positive control. 
Results
Immunohistochemical results and signalment data are
summarized in table I.
Mammary samples were obtained by 39 female cats; 27
were European cats, 9 Siamese cats, 2 Persian and 1 un-
known breed. Animals were aged from 6 to 15 years (age
not reported in one case), with an average age of 11 years
and 5 months.
Sox9 nuclear immunostaining was detected in all sam-
ples (figure 1), but one (case n. 25). This solid carcinoma
showed weak rare Sox9 positivities in hair follicles,
demonstrating sample reactivity. In 10 FMCs, immunore-
activity was present in less than 10% of cells, in 9 cases in
10-50% of cells and in 19 samples in more than 50% of
cells. Signal intensity was scored as weak in 10 FMCs,
moderate in 14, and intense in 14 cases. Total score ob-
tained were 9 (10 cases), 6 (9 cases),4 (3 cases), 3 (4 cases),
2 (8 cases), 1 (4 cases), 0 (1 case).
Discussion
In this investigation, 39 FMCs have been investigated for
Sox9 expression. According to our signalament data,
prevalence of FMC in male cats are lower than the re-
ported data of 1-5%. Sox9 was expressed in almost all
FMC, but one. Sox9 detection was variable according to
the number of positive cells and immunostaining intensity.
Results obtained can be divided in 3 groups: negative or
low positivity FMCs (total scores 0-2: 13 cases), interme-
diate FMC positivity (total scores 3, 4: 7 cases), high FMC
positivity (total scores 6-9: 19 cases). It emerges that al-
most half of the FMC of this study shows high Sox9 im-
munoreactivity. 
Sox9 has been suggested to be implicated in breast can-
cer development and progression (Guo et al., 2012;
Riemenschnitter et al., 2013; Wang et al., 2013; Fazilaty
et al., 2015; Pomp et al., 2015). This transcriptor factor is
often detected in mammary basal-like o triple-negative
carcinomas (Riemenschnitter et al., 2013; Wang et al.,
2013), and its expression, nuclear (Guo et al., 2012; Fazi-
laty et al., 2015; Pomp et al., 2015) or cytoplasmic
(Chakravarty et al., 2011a,b), is associated to metastases
and a poor prognosis. Up to now no data about this issue
are available in veterinary medicine. With regard to our
previous work on normal feline mammary gland, feline
mammary hypertrophy (FMH) cases and other cat dys-
plastic/hyperplastic lesions (data reported above in this
thesis), results demonstrate that Sox9 is present, with vari-
able pattern, even in non-neoplastic diseases; Sox9 indeed
regulates mammary stem cells activity in normal mam-
mary gland too (Guo et al., 2012; Ye et al., 2015). Intense
and diffuse Sox9 signal was observed in all FMH cases, a
non-neoplastic proliferation of the mammary gland of the
cat characterized by sudden and rapid onset (Hayden et
al., 1981). This observation may support the hypothesis
that, in mammary pathologies, Sox9 high expression alone
is not able to induce a neoplastic condition, either benign
or malignant. Sox9 exhibit its regulatory functions forming
complexes with other transcription factors, with context-
dependent mechanisms, according to specific tissue and
target cells ( Jo et al., 2014). Among various signaling path-
ways cooperating with Sox9, as Wnt/β-Catenin or Notch,
Snail family with the transcription factors Snail and Slug
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in particular, activate different EMT program in MaSCs
(Guo et al. 2012; Ye et al., 2015). Slug overexpression has
been previously associated to poor prognosis in human
breast cancer lines (Guo et al. 2012), but Snail expression
results in even a higher number of tumor initiating cells
and metastases (Ye et al., 2015); this findings leads to new
and different considerations of prognostic significance of
Slug in mammary neoplasms. High levels of Slug reported
were related to basal differentiation, classical feature of ag-
gressive tumor (Ye et al., 2015).
The findings of this investigation complement those of
the earlier study on FMH and other cat dysplastic/hyper-
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Figure 1. Sox9 immunohistochemical staining in FMC. Intense positivity detected in tubulopapillary (A), cribriform (B) and
solid (C) carcinomas, with total scores 9. (D) Weak Sox9 positivity (total score 3) in a tubulopapillary carcinoma. (E) Solid carci-
noma with moderate Sox9 immunostaining (total score 6). Haematoxylin counterstain (obj. 20 x).
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plastic lesions, but further characterization of FMC is
needed, investigating a possible correlation between triple
negative phenotype (negativity for estrogen receptor, prog-
esterone receptor and HER-2) and Sox9 expression in
FMC, in order to define its prognostic significance. It
would be interesting, moreover, to assess the expression of
Slug and Snail in normal tissue, neoplastic and displastic
lesions of mammary gland, to better understand the com-
plex interactions of Sox9 with its regulators.
Role of the transcription factor SOX9 in the tumorigenesis of some domestic animal neoplasms
Table I. Sox9 immunohistochemical results and signalment of cats. NA = not available.
Case FMC Breed Age Percentage Intensity Total Score
1 Tubulopapillary Siamese 10 2 3 6
2 Tubulopapillary Siamese 10 3 3 9
3 Tubulopapillary European 8 3 3 9
4 Tubulopapillary European 14 3 3 9
5 Tubulopapillary European 12 1 2 2
6 Tubulopapillary European 11 1 1 1
7 Tubulopapillary European 15.5 3 2 6
8 Tubulopapillary European 10 3 3 9
9 Tubulopapillary European 10 3 3 9
10 Tubulopapillary Siamese 13 3 3 9
11 Tubulopapillary European NA 3 2 6
12 Tubulopapillary Persian 14 3 2 6
13 Tubulopapillary Siamese 10 3 2 6
14 Tubulopapillary European 6 2 2 4
15 Tubulopapillary Siamese 13 3 3 9
16 Tubulopapillary European 8 1 1 1
17 Tubulopapillary Siamese 11 1 2 2
18 Tubulopapillary Persian 14 2 1 2
19 Tubulopapillary European 13 1 1 1
20 Tubulopapillary NS 15 1 2 2
21 Tubulopapillary Siamese 10 3 1 3
22 Tubulopapillary European 13 1 3 3
23 Solid Siamese 13 3 3 9
24 Solid European 14 3 2 6
25 Solid Siamese 11 0 0 0
26 Solid European 9 3 1 3
27 Cribriform European 14 3 3 9
28 Cribriform European 12 2 2 4
29 Cribriform European 9 3 3 9
30 Cribriform European 13 2 3 6
31 Cribriform European 15 2 1 2
32 Cribriform European 9 1 1 1
33 Cribriform European 12 2 1 2
34 Cribriform European 6 1 2 2
35 Cribriform European 14 1 2 2
36 Cribriform European 10 3 1 3
37 Cribriform European 13 3 2 6
38 Complex ductal European 9 2 3 6
39 Complex ductal European 12 2 2 4
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Sox9 expression in canine mammary
neoplasms
Introduction
Master regulatory genes are transcription factors coordi-
nating the main phases of organism development. Sox9,
as previously explained, is involved in a wide variety of em-
bryonic developmental processes and in differentiation of
several tissues and organs, cartilage included (Akiyama et
al., 2004; Vidal et al., 2005; Sakai et al., 2006; Seymour et
al., 2007; Davis and zur Nieden, 2008; Akiyama, 2008;
Barrionuevo and Scherer, 2010; Antoniou et al., 2010;
Pritchett et al., 2011). Sox9 indeed has been demonstrated
to be of primary importance in the early phases of cartilage
differentiation from mesenchymal stem cells. It is widely
expressed in all differentiated chondrocytes until the cells
reach hypertrophy in the growth plate (Akiyama and
Lefebvre, 2011). Although Sox9 expression has been re-
ported in several adult organs such as intestine, pancreas,
testis and hair follicle (Nowak et al., 2008) its function in
postnatal tissues has not been completely elucidated. In
veterinary literature there is few data concerning the role
of Sox9 and Runx2, another master regulatory gene, in
dogs. Csaki et al. (2007) demonstrated that canine mes-
enchymal stem cells, treated with suitable induction media,
differentiate in chondrocytes and osteoblast, exhibiting
their own specific transcription factors too, represented re-
spectively by Sox9 and Runx2.
Benign mixed tumor is one of the most common neo-
plasm in female dogs. This neoplasm is composed by neo-
plastic epithelial cells morphologically similar to the
normal epithelial component of mammary gland, and by
mesenchymal cells giving rise to cartilage, bone or adipose
tissue, sometimes associated to fibrous tissue. Its malignant
counterparts, carcinoma and sarcoma in benign tumor,
recur too; in these neoplasms, foci of respectively epithelial
or mesenchymal neoplastic cells are present (Misdorp et
al., 1999). The origin of chondroid and osteoid component
in these neoplasms is still debated. Recent works suggest
a role of basal cells/myoepithelial cells or of the mammary
stem cells (Tateyama et al., 2001; Espinosa de Los Mon-
teros et al., 2002; Gama et al., 2003; Gama et al., 2004),
but mechanisms involved in osteochondrogenic process of
canine mixed mammary tumor are still unclear.
The objective of this work is to investigate the im-
munohistochemical localization of the master chondro-
genic transcription factor Sox9 in mammary tumors of
dog, to better assesses its role in the histogenesis of the
chondroid component in mixed tumors.
Materials and Methods
Case selection
Different histotypes of canine mammary tumors were re-
trieved from the files of the Department of Veterinary
Medicine. Samples of simple tubular adenoma (n=2),
complex adenoma (n=4), benign mixed tumor (n=7), car-
cinoma in mixed tumor (n=4), complex adenocarcinoma
(n=6), simple adenocarcinoma (n=4), anaplastic carcinoma
(n=1), solid adenocarcinoma (n=1) and osteochondroma
(n=1) were selected. Normal mammary tissue surrounding
the tumor was also included in the study. The diagnosis of
each tumor was revised according to the criteria of the
World Health Organization classification of Mammary
Tumors of the Dog and the Cat.
Immunohistochemical staining
Four-micrometer thick sections from routinely formalin-
fixed, paraffin-embedded tissue blocks were prepared on
poly-L-lysine–coated glass slides for immunohistochem-
istry. The sections were de-paraffinized in xylene and re-
hydrated through graded alcohols. Endogenous peroxidase
was blocked using 3% hydrogen peroxide in distilled water
for 5 min, then antigen retrieval for formalin-fixed samples
was accomplished by microwave irradiation in citrate
buffer (pH 6.0) for 10 minutes. Sections were incubated
for 18 hours at 4°C with anti-Sox9 antibody rabbit poly-
clonal antibody (Sigma, Product Number HPA001758)
diluted 1:200 followed by staining with streptavidin-biotin
peroxidase kit (Vectastain Elite ABC, Vector Laboratories,
Cat. # 6102 and 6105). Positive staining was visualized
SOX9 in mammary gland neoplasms
44 Role of the transcription factor SOX9 in the tumorigenesis of some domestic animal neoplasms
with 3.3 - diaminobenzidine-4 HCl (Vectastain, Vector)
and nuclei were counterstained with Mayer’s haema-
toxylin. Sox9 reactivity of follicular outer root sheath pres-
ent in normal cutaneous tissue of each tumor sample was
used as internal positive control, while sections incubated
under identical conditions with normal rabbit serum were
used as negative control.
Evaluation of immunohistochemical data
Immunohistochemical reaction of different neoplastic cell
types was evaluated: epithelial cells (EC), myoepithelial
cells (MEC), elongated or round solid myoepithelial cells
(SMEC), myxoid matrix with spindle or stellate cells
(MyxC), chondroblast/chondrocyte (Ch), osteoblast/os-
teocyte (Ost). Sox9 expression was classified into 4 groups
according to the proportion of positive cells: 0= no positive
cells; 1= <10% positive cells; 2= 10-50% of positive cells;
3= >50% of positive cells. Intensity was scored as nega-
tive=0; weak=1; moderate=2; intense=3. A total score was
conferred multiplying the positive cells percentage score
and the intensity of immunolabeling score. The percentage
of Sox9-positive cells and the intensity of labelling were
Case EC MEC SMEC MyxC Ch Ost
Simple tubular adenoma 1 0 NP NP NP NP NP
2 1 NP NP NP NP NP
Complex adenoma 3 0 0 0 0 NP NP
4 1 0 0 1 NP NP
5 1 0 NP 1 NP NP
6 1 0 0 0 NP NP
Benign mixed tumor 7 3 0 3 2 2 NP
8 2 2 NP 4 0 NP
9 2 0 0 1 0 NP
10 0 0 0 0 NP NP
11 0 0 0 0 NP 0
12 0 0 NP 1 0 NP
13 0 0 0 0 0 NP
Carcinoma in mixed tumor 14 2 1 1 1 2 NP
15 1 NP 2 NP 1 0
16 0 0 0 0 0 NP
17 6 0 6 NP 6 0
Complex adenocarcinoma 18 1 1 1 1 NP NP
19 0 0 1 0 NP NP
20 0 0 NP 0 NP NP
21 4 4 4 NP NP NP
22 1 0 0 0 NP NP
23 1 1 1 1 NP NP
Simple adenocarcinoma 24 9 NP NP NP NP NP
25 6 NP NP NP NP NP
26 9 NP NP NP NP NP
27 6 NP NP NP NP NP
Anaplastic carcinoma 28 0 NP NP NP NP NP
Solid carcinoma 29 0 NP NP NP NP NP
Osteochondroma 30 NP NP NP NP 0 0
Table 1. Total scores (percentage of positive cells x signal intensity) in different neoplastic cell types. NP = not present, EC = ep-
ithelial cells , MEC = myoepithelial cells, SMEC = elongated or round solid myoepithelial cells, MyxC = myxoid matrix with
spindle or stellate cells, Ch = chondroblast/chondrocyte, Ost = osteoblast/osteocyte.
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independently assessed by two researchers.
Results
Results of Sox9 immunolabeling in the different type of
cells are summarized in table 1.
One of two cases of simple tubular adenoma showed
weak Sox9 immunolabeling in neoplastic EC (total score
1).
In complex adenomas weak Sox9 positivity was present
in neoplastic ECs (3 out of 4 cases) and MyxCs (2 out of
4 cases) with total scores 1.
ECs in benign mixed tumor were Sox9 positive in 3 of
7 cases (total scores ranging from 2 to 3) (Fig. 1A), MECs
and SMECs in 1 out of 7 cases (total scores of 2 and 3 re-
spectively), MyxC in 4 of 7 cases (total scores from 1 to 4)
and Ch in 1 of 7 cases (total score 2).
In carcinoma in mixed tumor cases, Sox9 was detected
in ECs, SMECs and Ch (3/4 of cases) (Fig. 1B) with total
scores from 1 to 6; in MECs and MixCs in 1/4 of cases
(total score 1).
Complex adenocarcinomas were positive for Sox9 in
neoplastic ECs and SMECs (4/6 of cases) (Fig. 1C) with
total scores from 1 to 4, in MECs in 3/6 cases (total scores
from 1 to 4) and in MixCs in 2/6 cases (total scores 1).
Simple adenocarcinoma showed strong Sox9 immuno-
labeling in ECs (4/4 cases) (Fig. 1D) with total scores
ranging from 6 to 9.
Osteochondroma, anaplastic and solid carcinoma were
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Figure 1. Sox9 immunohistochemistry in canine mammary gland neoplasms, haematoxylin counterstained. (A) Benign mixed
tumor with moderate and scattered immunolabeling in ECs and MECs, diffuse in MyxC (obj. 20 x). (B) Carcinoma in mixed
tumor with rare positivities of MyxCs next to the fibrocartilaginous area and of few undifferentiated chondrocytes (obj. 20 x). (C)
Complex adenocarcinoma with moderate positivity especially in ECs (obj. 20 x). (D) Simple adenocarcinoma with strong im-
munolabeling in neoplastic ECs (obj. 10 x).
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all Sox9 negative.
Most of Sox9 positivities were detected in ECs.
Among benignant and malignant mixed tumors, Sox9
showed Ch immunolabeling in 4/11 cases (case n 17
showed the highest total scores).
Ectatic ducts and lobular hyperplasia were also present
at the periphery of neoplastic tissue of in cases n°30 and
n°8 respectively. ECs and MECs of ectatic ducts showed
few cells with moderate Sox9 positivity, while in lobular
hyperplasia an intense and diffuse immunolabeling was
observed.
Discussion
The aim of the study was to examine the expression of the
transcription factor Sox9 in canine mammary tumors to
establish if Sox9 plays a role in histogenesis of chondroid
tissue of mixed tumor. Obtained data is somewhat surpris-
ing and unexpected.
According to the literature, the highest Sox9 immuno-
labeling was expected in chondrocytes and various cell
types (solid myoepithelial cells, spindle/stellate cells in
myxoid areas) involved in cartilage histogenesis.
Sox9 was detected in many different mammary tumors,
but especially in the epithelial cells of simple carcinoma
show a diffuse and strong Sox9 expression. Similar results
have been recently described in human medicine by
Chakravarty et al. (2011a,b) and Guo et al. (2012) and
similar results also come out from the evaluation of sox9
expression in feline mammary carcinomas reported in the
previous part of this thesis. They demonstrated a Sox9
over-expression in the most malignant breast carcinomas.
A possible explanation for this, as suggested by Guo et al.
(2012), might be that Sox9 is involved in epithelial-mes-
enchymal transition mechanisms, that are associated to
high-grade malignancy, including motility, invasiveness
and increased resistance to apoptosis.
Anyway, Sox9 immunohistochemical detection was
found in a large number of both malignant and benign tu-
mors; higher Sox9 positivity and immunolabeling intensity
were present especially in the malignant ones.
Sox9 expression in tumors with solid groups of spin-
dle/round myoepithelial cells or spindle/stellate cells in
myxoid matrix, was variable, from undetectable to
weak/moderate in few scattered cells. It may be that even
this low Sox9 expression leads cells to chondroid differen-
tiation. An analogous Sox9 expression pattern has been
observed in benign mixed tumor chondrocytes ad in car-
cinomas in benign mixed tumor. A possible explanation
for this finding might be that, in these neoplasms, other
chondrogenic transcription factors as Sox5, Sox6, Bmp2
and Bmp7 contribute to cartilage formation (Csaki et al.,
2007; Akiyama, 2008; Nishimura et al., 2012).
As expected, osteocytes and osteoblasts were unrespon-
sive to Sox9. A possible role of other transcription factors
(i.e. TGF-b, Bmp2, FGF2 and Runx2) in bone-osteoid
histogenesis has to be considered (Davis and zur Nieden
2008; Komori 2010; Chen et al. 2012).
These findings, while preliminary, suggest that:
1) Sox9 expression is often detected, in variable in-
tensity, in epithelial luminal cells of dog mammary tumor.
2) Sox9 protein expression is pronounced in simple
carcinoma, tumor characterized by high malignancy. Sox9
may be investigated as an interesting malignancy marker.
To confirm this data, further studies, with a wider number
of cases need to be undertaken.
3) A low grade of Sox9 expression is detectable in
benign mixed tumors and carcinoma in benign mixed
tumor, where often cartilagineous tissue is found. In this
case too, further research should be done; the present find-
ing, indeed, is comparable to the results obtained by Kusa-
fuka et al. (2008) in four cases of brest matrix-producing
carcinoma in human medicine.
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Immunohistochemical panel evaluation
for differential diagnosis of horse spin-
dle cells tumors
Introduction
SoxE and nervous tissue
Sox E proteins, as previously said, include Sox8, Sox9 and
Sox10 (Wright et al., 1995); regarding nervous tissue for-
mation, they play multifunctional roles in neural crest for-
mation and development regulation (Haldin and
LaBonne, 2010). In addition to promote neural crest for-
mation, they play a central role in the formation of various
neural crest derivates, as skin pigment cells, glial cells,
oligodendrocytes, cartilage and components of peripheral
and enteric nervous system (Chew and Gallo, 2009;
Haldin and LaBonne, 2010).
After the neural tube closure, multipotent neural crest
stem cells (NCSCs) arise from the neural plate, a transient
structure present at the junction of epidermal and neural
ectoderm (Kipanjula et al., 2014).
NCSCs can be considered as a transient migratory
population of stem cells that originates from cells in the
dorsal neural folds at the border of the neural plate and
epidermal ectoderm (Cheung and Briscoe, 2003). Follow-
ing epithelial to mesenchymal transition (EMT), they mi-
grate throughout the early embryo and give rise to a wide
set of derivatives (Cheung and Briscoe, 2003; Haldin and
LaBonne, 2010; Kipanjula et al., 2014), notably neurons
and myelinating glia of the peripheral nervous system, as
well as the entirety of enteric nervous system (Haldin and
LaBonne, 2010). They are responsible for neuroendocrine
cells formation, differentiation of melanocytes of the skin,
mesenchymal tissues and cartilage (Haldin and LaBonne,
2010; Kipanyula et al., 2014). SoxE factors are versatile
transcription factors; they maintain cell multipotency and
at the same time instruct the differentiation of multiple
neural crest derivates (Haldin and LaBonne, 2010).
In vivo and in vitro studies suggest that formation, mi-
gration, survival, differentiation and specialization of
NCSCs are under control of: environmental factors, re-
lated to the presence of specific signaling molecules, and
intrinsic signals, mediated by specific transcription factors
and the related target genes and proteins (Kipanyula et al.,
2014). 
Despite the complexity of the signaling mechanism,
emerging experimental evidence suggest that induction of
neural crest formation and its subsequent delamination
can be ascribed to the interaction of SoxE with (i.e.) bone
morphogenetic protein (BMP), fibrocyte growth factor
(FGF) and proto-oncogenic molecules of Wnt e Hedge-
hog (Hh) families for its formation; Slug, Snail and FoxD3
for cell migration (Kipanyula et al., 2014).
Sox9 and nervous tissue
Sox9 is required for both formation and maintenance of
nervous staminal cells during embryogenesis and for glial
cells determination in central nervous system (Haldin and
LaBonne, 2010). Sox9 expression in staminal cells and in
neuroepithelial cells precedes the onset of gliogenesis
(Stolt et al., 2003) and participates to EMT process prior
to neural crest delamination (Cheung et al., 2005).
In case of Sox9 absence, neural epithelial cells forming
neural crest undergo apoptosis prior to or shortly after de-
lamination (Cheung et al., 2005). Hierarchical correlation
among various genes involved in neural crest formation
need to be clarified yet, but it seems that Sox9 plays a piv-
otal role in EMT regulation through interaction and acti-
vation of Snail2. This transcription factor inhibits
E-cadherin expression, encouraging in this way cellular
differentiation (Cano et al., 2000; Sakai et al., 2006). Sox9
is important not only for the generation of neural crest,
but even for gliogenesis (Stolt et al., 2003). In the central
nervous system, myelin-forming oligodendrocytes and
non-myelinating astrocytes represent the two main types
of glia (Stolt et al., 2003; Scott et al., 2010). These neuronal
subtypes arise from two different compartment of the ven-
tricular zone (Stolt et al., 2003). Astrocytes preserve Sox9
expression till adulthood; a different behavior is observed
in oligodendrocytes. Oligodendrocytes progenitors are
Sox9 positive; Sox9 expression, that together with Olig2
is essential for oligodendrocytes specification, is main-
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tained in migrating and proliferating oligodendrocytes.
Sox9 disappears in terminal differentiation. Its expression
in oligodendrocytes, thus, is transient: in adult nervous tis-
sue Sox9 is found neither in oligodendrocytes, nor in neu-
rons (Stolt et al., 2003). Experimental studies
demonstrated that the absence of Sox9 causes a reduction
in the number of glial cells and an increase in the number
of neurons; this because Sox9, together with Sox8, modi-
fies neuroepithelial progenitors features in the ventricular
zone and is involved in the neuron-glia switch in the de-
veloping spinal cord (Wegner and Stolt, 2005; Pritchett et
al., 2011). Forced Sox9 or SoxE genes expression induces
an ectopic differentiation of neural crest, at the expense of
central nervous system neuronal generation (Cheung and
Briscoe, 2003).
Sox10 and nervous tissue
Sox10 has been studied first in human medicine as related
to congenital anomalies (Pingault et al., 1998). Sox10 mu-
tations cause several different neurocristopathies; in par-
ticular, an important association with central and
peripherical myelin deficiency and with Waardenburg syn-
drome has been described. This genetic disorder is charac-
terized by heterochromia of the irises, hypopigmentation
of the skin, deafness, and sometimes is concurrent with
Hirschsprung’s disease (aganglionic megacolon). It is often
defined as PCWH (Peripheral demyelinating neuropathy-
Central dysmyelinating leukodystrophy-Waardenburg
syndrome-Hirschsprung disease) (Pingault et al., 1998;
Kelsh, 2006). Sox10 is involved in NCSCs formation, spe-
cialization and subsequent differentiation (Kelsh, 2006),
in addition to be essential for early development of
Schwann cells from neural crest (Svaren and Meijer, 2008).
Sox10 expression has been detected in the emerging
neural crest (Kuhlbrodt et al., 1998). Sox10 is essential for
maintenance of stem cell state: it is able to inhibit overt
differentiation, preserve proliferative abilities and NCSCs
multipotency (Kim et al., 2003). Sox10 seems to be in-
duced by Sox9 prior that neural crest cells start migration
( Cheung et al., 2005; Stolt and Wegner, 2015) and, once
induced, it is maintained transiently in migrating cells
(Kelsh, 2006). Sox10 remains expressed in NCSCs and in
cells that are destined for glial, schwannian, and
melanocytic differentiation (Shin et al., 2012; Stolt and
Wegner, 2015), while its expression, instead, is extin-
guished in non glial-cells, as in cells oriented to neuronal
or smooth muscle differentiation (Kim et al., 2003; Shin
et al., 2012).
In the central nervous system Sox10, together with
Sox8, plays a crucial role in terminal differentiation of
oligodendrocytes, while Sox9 acts during the early stages
(Stolt et al., 2003).
Sox10 in NCSCs mediates peripheral glial fate,
melanocytic fate, autonomic and enteric neurons fate in a
context dependent way, by means of interactions with dif-
ferent intrinsic signaling molecules and specific environ-
mental signals for fine-tuning lineage decisions (Kelsh,
2006; Kipanyula et al., 2014). One of the glial components
of the peripheral nervous tissue is represented by Schwann
cells, whose precursors differentiation involves interactions
of Sox10 with factors as Notch1 and NRG. Maturation of
Schwann cells in non-myelinating Schwann cells and in
myelinating Schwann cells is mainly directed respectively
by Oct-6, EGR2/Krox-20 and Pax3 signaling (Kipanyula
et al., 2014).
In normal adult tissues, SOX10 expression was re-
ported in Schwann cells of the peripheral nerves,
melanocytes of the epidermis, oligodendrocytes of the
cerebral cortex, enteric ganglia, sympathetic ganglia, sen-
sory ganglia, mast cells, myoepithelial cells of the submu-
cosal bronchial glands and breast, acinar and myoepithelial
cells of the salivary glands (Kuhlbrodt et al., 1998; Wegner
and Stolt, 2005; Ordóñez, 2013).
Sox9, Sox10 and nervous tissue neoplasms
Neoplastic cells often show characteristics similar to those
of the progenitor cells they come from; for this reason
master regulatory genes as Sox9 and Sox10 are often de-
tected in neoplastic lesions related to tissues they guide the
development of, nervous tissue included (Matheu et al.,
2012).
In a immunohistochemical study performed on sam-
ples of Schwannomas, neurofibromas, and malignant pe-
ripheral nerve sheath tumors (MPNSTs), Sox9 and Sox10
have been widely detected in all tumor types considered
(Pytel et al., 2010). These 3 tumors represent neoplastic
proliferations of cells with Schwannian differentiation, so
that Sox9 and Sox10 appear to be sensitive markers of
Schwannian differentiation (Pytel et al., 2010).
In another study by Miller et al., (2009) Sox9 was
found to be overexpressed in peripheral nerve sheat tumors
(PNST) of patients with neurofibromatosis1 (NF1). An-
other study suggested that even if Sox9 is not a specific
feature of neurofibromatosis 1 tumors, it could play a role
in the development of MPNST in patients with neurofi-
bromatosis 1 (Carbonnelle-Puscian et al., 2011).
Sox9 was expressed at higher levels in MPNST than
NF1-derived primary benign neurofibroma Schwann cells.
Malignant transformation seems to be related to a higher
Sox9 transcriptional activity in MPNST cells associated
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to a reduced expression of Sox10 (Miller et al., 2009).
Reduced expression of Sox10 in NF1 tumors suggests
that this decreased expression may be necessary for tumor
formation. Low Sox10 presence in Schwann cell tumors
is also consistent with failure of complete differentiation
(Miller et al., 2009).
Strong immunohistochemical positivity for Sox9 and
Sox10 has been detected in central neuroepithelial tumors
at high grade of malignancy, while reactive astrogliosis was
characterized by an increase of Sox9 only (Kordes and
Hagel, 2006).
Sox10, because of its restricted expression in normal
tissues, is commonly expressed in melanomas, tumors with
Schwann cell differentiation, and in salivary gland neo-
plasms (Ordóñez, 2013). Gershon et al. (2005) demon-
strated Sox10 presence in tumors arising from neural crest,
especially for the melanocytic ones. Subsequent studies
confirmed Sox10 as a marker for benign and malignant
melanocytic lesions of several subtypes to distinguish them
from fibrohistiocytic and histiocytic proliferations (Shin
et al., 2012). Among epithelial neoplasms, Sox10 was
found strongly positive in myoepithelial or basal cell–re-
lated neoplasms, especially in salivary gland benign and
malignant tumors (Ohtomo et al., 2013; Miettinen et al.,
2015). Sox10 has been investigated as a marker for brest
cancer too (Dravis et al., 2015).
There is few literature concerning the expression of
Sox10 in tumors of the nervous system, but published re-
sults indicate that this gene is commonly expressed in
Schwannomas (100%), neurofibromas (98% to 100%) and,
less frequently, in MPNSTs (50% to 55%) (Ordóñez,
2013). As previously said, Sox9 and Sox10 are considered
good markers for Schwann cell differentiation (Pytel et al.,
2010). Comparing Sox10 and S-100 for melanomas and
peripheral nerve sheath tumors diagnosis, it has emerged
that Sox10 nuclear expression was found in 97% of
melanomas, 49% of MPNST, whereas S-100 protein was
expressed in 91% of melanomas and 30% of MPNST.
Sox10 moreover was diffusely expressed in schwannomas
and neurofibromas. Sox10 is considered as a more sensitive
and specific marker for the diagnosis of melanocytic and
schwannian tumors, especially of MPNST, than S100
(Nonaka et al., 2008; Karamchandani et al., 2012). In a re-
cent study in human medicine Sox10 resulted a specific
marker (93% positivity), but not so sensitive (67% positiv-
ity) for the diagnosis of MPNST and for differential di-
agnosis with sinovial sarcomas (Kang et al., 2014).
Horse spindle cells tumors
Horse spindle cells tumors are comprehensive of a wide
range of mesenchymal neoplasms and not only, that in-
clude tumors of fibroblastic origin, as sarcoids, muscular
neoplasms, vascular neoplasms, arising from peripheral
nerve sheats and even melanocytic (Scott et al. 2011).
In the present study, the most common skin spindle
cell neoplasm of the horse, the sarcoid, and neoplasms
where a differential diagnosis is often needed, as peripheral
nerve sheath tumor (PNST), malignant peripheral nerve
sheat tumors (MPNST) and, rarely, other soft tissue sar-
comas (Scott et al., 2011) have been investigated. Cur-
rently differentiation of these neoplasms is mainly based
on their histopathological phenotype but, in horse as in
dog, several immunohistochemical markers have been pro-
posed especially to distinguish fibroblastic tumors from
PNSTs (Bogaert et al., 2011; Meyer and Klopfleisch,
2014).
PNST
Benign peripheral nerve sheath tumor (PNST) represent
an heterogeneous group of neoplasms originating from
Schwann cells, fibroblasts or perineural cells (Sturgeon et
al., 2008). PNST are relatively common in human beings,
but occur infrequently in domestic animals (Quinn et al.,
2005).
In human medicine PNSTs are classified in 4 types:
schwannoma (or neurilemmoma), neurofibroma, perineu-
rioma, and ganglioneuroma. They show characteristic di-
agnostic features, and different prognosis and treatment
(Schöniger et al., 2011). In addition to these forms, neu-
rofibromatosis type1 (NF1) has been identified; this is an
inherited disorder characterized by the presence of multi-
ple dermal or plexiform neurofibromas. These patients are
at higher risk for neoplastic differentiation than the gen-
eral population, especially for MPNST development
(Thway and Fisher, 2014).
In veterinary medicine, according to the World Health
Organization International Histological Classification of
tumors of domestic animals, PNST are divided in benign
forms (schwannoma -PNST- and neurofibroma) and ma-
lignant forms (malignant schwannoma -MPNST- and
neurofibrosarcoma) according to their histogenesis (Koest-
ner et al., 1999).
Nevertheless, in veterinary literature, the terms benign
PNST, schwannoma, and neurofibroma are often used in-
terchangeably (Schöniger et al., 2011). It seems that all
PNSTs show a similar clinical behavior, but the criteria to
distinguish among them are not well established for ani-
mals yet (Schöniger et al., 2011). Some Authors believe in
an increased complexity of benign PNST in animals and
are trying to improve diagnostic criteria for their subclas-
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sification (Koestner et al., 1999, Schöniger et al., 2011;
Schöniger and Summers 2009).
PNSTs are most often reported in dogs and cattle
(Schöniger and Summers 2009), while are said to be rare
in horse: they account for 1,1 to 5% of the equine cuta-
neous neoplasms in various surveys (Scott et al., 2011;
Schöniger et al., 2011).
Schwannoma
Schwannomas arise from the myelinating cell of the pe-
ripheral nervous system and are composed almost entirely
of Schwann cells; they typically grow within a capsule that
remains peripherally attached to the parent nerve (Wip-
pold II et al., 2007).
Antoni A and Antoni B tissue patterns are character-
ized respectively by densely packed neoplastic cells and
poorly cellular areas of fusiform neoplastic Schwann cells
in a stroma that is either collagenous and scant, or is myx-
oid and abundant (Schöniger and Summers 2009). In An-
toni A areas nuclear palisading and Verocay bodies may be
detected (Schöniger et al., 2011).
Neurofibroma 
Neurofibromas contain a mixture of all the cellular ele-
ments of a peripheral nerve, including Schwann cells, fi-
broblasts, perineurial cells, and axons. Tumor cells grow
diffusely within and along nerves, causing the nerves to
expand radially while entrapping native neural elements
within the substance of the tumor (Wippold II et al.,
2007).
MPNST
Malignant peripheral nerve sheath tumor (MPNST) are
soft tissue neoplasms that usually arise from peripheral
nerves and show variable histological patterns according
to the cellular components of the nerve sheath (Schwann
cells, fibroblasts, and perineural cells) they arise from
(Thway and Fisher, 2014). In veterinary medicine these tu-
mors occur infrequently (Quinn et al., 2005), but they are
most commonly seen in dogs. They usually involve the
brachial or lumbar plexus, often compressing and invading
the spinal cord and brain (Koestner et al., 1999). In horses,
they have been described extradurally within the cranium
and invading the cervical spinal cord, mediastinum, gas-
trointestinal tract, skin, periocular tissues and heart (Quinn
et al., 2005). Histologically, cells are arranged in fascicles,
whorls, or sheets, and range from spindle-shaped to plump
fusiform cells with variable amount of fibrillar collagenous
stroma to epithelioid arrangements. These differentiated,
pleomorphic, anaplastic populations of cells infiltrate ad-
jacent tissues or metastasize to other organs (Stoica et al.,
2001). MPNSTs indeed represent a heterogeneous group
of neoplasms with a wide range of morphology; in human
medicine they are often aggressive tumors with a tendency
to recur and metastasize (Thway and Fisher, 2014), while
in animals these tumors commonly recur after excision,
but metastasis is rare (Koestner and Higgins, 2002). Due
to their morphologic heterogeneity and the lack of specific
immunohistochemical or molecular markers, histologic di-
agnosis is challenging (Thway and Fisher, 2014). Schwan-
nomas lacking these classical morphologic patterns are
often difficult to differentiate from other spindle cell tu-
mors such as fibroma, canine hemangiopericytoma, fibrous
histiocytoma, melanosarcoma, and leiomyoma/leiomyosar-
coma (Stoica et al., 2001). MPNSTs show positive im-
munohistochemical staining for Vimentin, NSE, S-100
and variable for GFAP (Kirchhof et al., 1996; Quinn et
al., 2005; Maxie and Sameh, 2007).
Sarcoid
Sarcoid is a common, locally aggressive, typically non-re-
gressing, fibroblastic cutaneous neoplasm of the horse. It
is the most common skin neoplasm of the horse, account-
ing for 35,3 to 90% of the total in numerous surveys (Scott
et al., 2011).
Sarcoids can occur anywhere on the body, but they are
detected especially on the head, lips, legs, and ventral trunk
(Koestner and Higgins, 2002) and in areas subjected to
traumatisms as wounds, tack or insects (Scott et al., 2011).
The pathogenesis of equine sarcoids is the result of a
nonproductive infection with bovine papillomavirus types
1 and 2 (Koestner and Higgins, 2002; Scott et al., 2011).
Histologically, most lesions are composed of a thickened
epidermis with prominent epithelial pegs that extend into
a dermal proliferation of fibroblasts arranged in arranged
in whorls, tangles, and/or herringbone patterns and con-
taining small amounts of collagen (Bogaert et al., 2011;
Scott et al., 2011).
The gross appearance of sarcoids can be quite variable,
but six broad categories are recognized: occult, verrucous,
nodular, fibroblastic, mixed and malignant (Scott et al.,
2011).
Because of sarcoid variability of dermal configuration,
especially in case of ulceration with loss of the distinctive
epidermal component, differential diagnosis with fibroma,
fibropapilloma, fibrosarcoma, neurofibroma, neurofibrosar-
coma, Schwannoma can be challenging (Koestner and
Higgins, 2002; Scott et al., 2011). A useful tool to improve
sarcoids diagnosis is represented by polymerase chain re-
action for bovine papillomavirus DNA (Bogaert et al.,
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2011).
Other differential diagnosis
Other differential diagnosis for equine spindle cells tumors
are represented by fibromas, fibrosarcomas, leiomyomas,
leiomyosarcomas, rhabdomyosarcomas, hemangiomas, he-
mangiosarcomas, hemangiopericytomas and other soft tis-
sues sarcomas (Maxie and Sameh, 2007).
Aim of the work
The aim of this work is to evaluate the usefulness of a
panel of immunohistochemical markers for neural differ-
entiation, including Sox9 and Sox10, for differential diag-
nosis of equine spindle cells tumors.
Materials and methods
Tissue samples
For this retrospective preliminary study, samples of paraf-
fin blocks of formalin-fixed horse spindle cell tumors were
retrieved from the archives of the Department of Veteri-
nary Medicine in a period going from 1998 to 2015. Tu-
mors identified with a diagnosis of: PNST (schwannoma,
neurofibroma) (n=18), MPNST (malignant schwannoma,
neurofibrosarcoma) (n=2), undifferentiated sarcoma (n=1)
and sarcoid (n=6) were selected. A limited number of sar-
coids (n=6) was selected for comparison. The diagnosis of
each tumor was revised according to the criteria of the
World Health Organization classification.
Four-micrometer thick sections were prepared on poly-
Figure 1. Immunohistochemical expression of Sox9 (A, C) and Sox10 (B, D) in PNSTs (A, B) and MPNSTs (C, D). Haematoxylin
counterstain (A, B, D = obj. 20 x; C = obj. 10 x).
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L-lysine–coated glass slides for immunohistochemistry.
Immunohistochemistry was performed using the avidin-
biotin-peroxidase complex (ABC) method (Vectastain
ABC Kit, Vector Laboratories Inc., Burlingame, CA,
USA).
The immunohistochemical panel included rabbit poly-
clonal antibodies against glial fibrillary acidic protein
(GFAP, 1 : 25000, Dako Denmark A/S, Glostrup, Den-
mark), S-100 protein (1 : 10000, Dako) , neuron-specific
enolase (NSE, 1:25, Dako), Sox9 protein (1:200,
HPA001758; Sigma-Aldrich, St. Louis, MO, USA), goat
polyclonal antibody against Sox10 protein (1:200, (N-20):
sc-17342 Santa Cruz Biotechnology, Inc.), and mouse
monoclonal antibodies against Vimentin (clone 3B4,
1:1000, Dako). The Sox9 antibody employed recognizes a
specific peptide with 98% identity with Equus caballus;
Sox10 antibody is recommended for detection of Sox-10
in a variety of species, including equine.
Concerning GFAP, NSE, S-100 and Vimentin (VIM),
tissue sections were immersed in a pre-heated solution at
94°C of Dewax and HIER Buffer H (Thermo Fischer Sci-
entific, Lab Vision Corporation, Fremont, CA, USA) di-
luted 1:15 with deionized water for 40 minutes. This
solution is designed to simultaneously dewax and perform
heat induced epitope retrieval.
Sox9 and Sox10 sections were deparaffinized in xylene
and rehydrated through graded alcohols. Antigen retrieval
was accomplished by microwave irradiation in 0,01 M cit-
rate buffer, pH 6.0, for 10 min. Endogenous peroxidase
SOX9 SOX10
Histological diagnosis Case n. VIM S-100 GFAP NSE A B C A B C
PNST
1 + + + - 3 2 6 0 0 0
2 + + - - 2 2 4 4 2 8
3 + + - - 3 2 6 4 2 8
4 + + - + 3 1 3 4 2 8
5 + + - + 1 1 1 3 2 6
6 + + + + 1 1 1 3 2 6
7 + + - - 4 3 12 4 3 12
8 + + + + 4 2 8 4 2 8
9 + + + + 1 1 1 2 1 2
10 + + - - 2 2 4 0 0 0
11 + - - - 1 2 2 2 2 4
12 + + + - 3 1 3 4 3 12
13 + + - + 4 2 8 4 3 12
14 + + + - 2 3 6 4 1 4
15 + + - - 4 3 12 4 3 12
16 + + - + 4 3 12 3 1 3
17 + + - + 3 2 6 4 3 12
18 + + - - 3 3 9 0 0 0
Sarcoid
1 + + - - 4 2 8 3 2 6
2 + + - + 1 1 1 0 0 0
3 + + - - 2 2 4 3 1 3
4 + - - + 0 0 0 0 0 0
5 + - - + 0 0 0 3 2 6
6 + - - + 2 3 6 3 2 6
MPNST
1 + - - - 2 3 6 0 0 0
2 - + + + 4 3 12 3 2 6
Undifferentiated sarcoma 1 + + + + 2 2 4 2 1 2
Table I. Immunohistochemical results divided for tumor type. + = positive; - = negative; A = % of positive cells; B = immunolabeling
intensity; C = product of A and B.
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was blocked using 1% hydrogen peroxide in Tris buffer for
45 min. Sections were incubated for 18 hours at 4°C with
primary antibodies. After incubation with the secondary
biotinylated immunoglobulin (diluted 1:200; Vector Lab-
oratories, Inc.) for 30 min, the avidin–biotin–peroxidase
complex method (Vector Laboratories, Inc.) was per-
formed. Positive staining was visualized with 3.3-di-
aminobenzidine-4 HCl (Vectastain, Vector Laboratories,
SK-4100) and nuclei were counterstained with Mayer’s
hematoxylin. Negative control sections were produced by
omission of the primary antibody.
Evaluation of immunohistochemical data 
The immunohistochemically stained tissue slides were ex-
amined using standard light microscopy.
Histological
diagnosis
Antibody Positivity %
PNST
n=18
VIM 18/18 100%
S-100 17/18 94%
GFAP 6/18 33%
NSE 8/18 44%
SOX9 18/18 100%
SOX10 15/18 83%
Sarcoid
n=6
VIM 6/6 100%
S-100 3/6 50%
GFAP 0/6 0%
NSE 4/6 67%
SOX9 4/6 67%
SOX10 4/6 67%
MPNST
n=1
VIM 1/2 50%
S-100 1/2 50%
GFAP 1/2 50%
NSE 2/2 100%
SOX9 2/2 100%
SOX10 1/2 50%
Undifferentiated
sarcoma
n=1
VIM 1/1 100%
S-100 1/1 100%
GFAP 1/1 100%
NSE 1/1 100%
SOX9 1/1 100%
SOX10 1/1 100%
Table II. Immunohistochemical results divided for type of
tumor and antibody employed.
GFAP, NSE, S-100, Vimentin immunoreaction was
evaluated as positive (+) or negative (-). Sox9 and Sox10
protein expression were assessed by categorizing im-
munoreaction of each tumor into five groups according to
the proportion of positive cells: 0, no positive cells; 1, from
1% to 25% positive cells; 2, from 25% to 50%; 3, from 50%
to 75%; 4, from 75% to 100%. The intensity of labeling was
graded as: W, weak positive staining; M, moderate positive
staining; I, intense positive staining, and scored as follows:
W=1, M=2, I=3. A global score was conferred multiplicat-
ing the positive cells percentage score and the intensity of
immunolabeling score.
Results
Immunohistochemical results are reported in the tables
above (Table I and II).
Sarcoid
The 6 sarcoids selected were positive for vimentin (100%),
50% of samples showed immunoreactivity for S-100, 67%
for NSE, but GFAP immunolabeling was absent. No one
of the samples showed a complete immunoreactivity for
all the neural markers employed, but they were positive for
at least one of them. Four sarcoids were Sox9 positive
(67%) with variable signal intensity and cell positivity. Four
sarcoids were Sox10 immunoreactive too (67%): 3 cases
with total score 6 and 1 case with total score 1. Positive
samples had a percentage of positive cells varying from 50
to 75% and a weak to moderate signal intensity.
PNST
PNSTs were all positive for vimentin (100%), and most of
them for S-100 (97%). 33% of cases was GFAP positive,
44% NSE positive. Three cases showed positive immuno-
labeling for vimentin, GFAP, NSE, S-100; 7 cases for vi-
mentin and at least two neural markers. Sox9 was detected
in 100% of samples (Fig. 1A). Sox9 total scores obtained
were: 12 (3 cases) (Fig. 1B), 9 (1 case), 8 (2 cases), 6 (4
cases), 4 (2 cases), 3 ( 2 cases), 2 (1 case), 1 (3 cases). Per-
centage of positive cells was variable: 0-25% in 4 cases, 25-
50% 3 cases, 50-75% 6 cases, 75-100% 5 cases. Samples
showed intense (5 cases), moderate (8 cases) and weak (5
cases), immunolabeling. Concerning Sox10, total score dis-
tribution was: 12 (5 cases), 8 (4 cases), 6 (2 cases), 4 (2
cases), 3 (1 case), 2 (1 case). Percentage of positive cells
varies from 25-50% (2 cases with intensity from weak to
moderate), 50-75% (3 cases with intensity from weak to
moderate), 75-100% (10 cases with intensity from mod-
erate to intense).
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tensity. These data may support Pytel et al. (2010) state-
ment, that Sox10 represents a more sensitive marker than
Sox9 for PNST diagnosis. In one case (n=11) neural mark-
ers resulted negative, mildly positive for Sox9 and Sox10,
positive for Vimentin: this immunohistochemical response
is similar to the one observed for sarcoids in this study.
Therefore this case should be better classified as sarcoid. 
Aa regards MPNST, one case was negative for Sox10
and S-100. Sox10 is considered a more reliable marker
than S-100 for neural crest tumors, especially regarding
PNST (Karamchandani et al., 2012; Kang et al., 2014).
High grade differentiation MPNST, in addition to be S-
100 negative, as in the present case, express Sox10 in 54%
of cases only (Ordóñez, 2013, Miettinen et al., 2015). In
the second MPNST case, Sox9 immunolabeling shows a
higher intensity than Sox10 one. Previous studies have
suggested that malignant transformation of PNST may be
related to a Sox10 downregulation and to an increase of
Sox9 expression (Miller et al., 2009; Pytel et al., 2010); due
to the low number of cases, no reliable hypothesis can be
advanced.
The undifferentiated sarcoma, previously diagnosed on
histological basis, without any immunohistochemical aid,
was positive to the whole immunohistochemical panel: vi-
mentin, neural markers, Sox9 and Sox10. In literature, a
case of undifferentiated sarcoma positive for Sox10 is re-
ported (Ordóñez, 2013), but in the light of these results
this tumor should be diagnosed MPNST.
All the sarcoids were vimentin-positive and variously
positive for neural markers. What is surprisingly is that 4
neoplasms were positive for Sox9 and Sox10 too. It has
been demonstrated that Sox9 is expressed in pathological
processes characterized by fibrosis (Pritchett et al., 2011);
Sox9 immunohistochemical positivity in mesenchymal
neoplastic cell may be related to its involvement in mech-
anisms of cellular proliferation. Sarcoid Sox10 immuno-
labeling in 4/6 cases instead, is unclear and unexplained.
Sox10 is detected in schwannomas, melanocytic neo-
plasms and in some myoepithelial neoplasms, but it is usu-
ally absent in other mesenchymal tumors (Miettinen et al.,
2015). Total scores were anyway lower than PNST ones. 
To my knowledge, this is the first time that Sox9 and
Sox10 have been employed in horse. They seem to be
promising markers for the diagnosis of PNST/MPNST
in horse, however further studies with a wider number of
records need to be carried out in order to better understand
the role of Sox9 and Sox10 in sarcoids and to validate de-
finitively these markers in veterinary medicine for
PNST/MPNST differential diagnosis.
MPNST
One of the 2 samples was positive for vimentin, S-100 and
GFAP; both were NSE positive. Sox9 showed positive im-
munolabeling in both cases with a percentage of positive
cells varying from 25 to 75% and intense immunostaining,
with total scores of 6 and 12 (Fig. 1C).
Sox10 was expressed in 1 case, with 50-75% of positive
cells and moderate intensity (total score 6) (Fig. 1D).
Undifferentiated sarcoma
The case selected was positive for vimentin, GFAP, NSE,
S-100. Sox9 and Sox10 were detected in 25-50% of cells
with moderate and weak intensity respectively.
Discussion
Spindle cell tumors of the horse are comprehensive of a
wide group of mesenchymal neoplasms that often repre-
sent a challenge for the pathologist. In most of cases they
are benign neoplasms, but due to gross and histological
similarities among sarcoids and PNST, immunohisto-
chemical examination is often needed to accurately diag-
nose those neoplasms. Markers as S-100, GFAP, NSE,
vimentin are commonly employed in veterinary medicine
for this purpose. The present study employed this ordinary
immunohistochemical panel with the support of Sox9 and
Sox10, markers of neural differentiation recently intro-
duced in diagnostic oncology, in order to evaluate the ap-
plication of this “enlarged panel” for the diagnosis of the
most common neoplasms of the neural crest.
In human medicine, Schwann cell tumors express both
Sox9 and Sox10 (Pytel et al., 2010). In particular, there is
a growing interest in these transcription factors because
morphological features of neurofibromas and low-grade
MPNSTs, that may arise within neurofibromas, are often
overlapping; moreover frequently morphological and im-
munohistochemical features distinguishing between MP-
NSTs and other sarcomas are frequently lacking (Pytel et
al., 2010).
According to the present results, Sox9 and Sox10 are
expressed in horse PNST and MPNST with variable in-
tensities. Sox9 immunolabeling is detectable in all PNST
cases, while Sox10 was present in 13/15 cases of PNST: 3
samples were negative for this marker despite variable im-
munostaining of the same cases to neural markers. Anyway
Sox9 seems to be expressed in a more uniform way than
Sox10, but with variable total score distribution. Sox10,
instead, when present, shows high positivity values and in-
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